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Abstract

Photodynamic therapy (PDT) is an FDA-approved, minimally invasive treatment
modality that utilizes light in the presence of oxygen to activate photosensitizing agents
to produce cell death. Phthalocyanine 4 (Pc 4), a second generation photosensitizer has
shown efficacy in vitro, in vivo and in a phase I clinical trial. Pc 4 localizes primarily to
mitochondria and endoplasmic reticulum, where it causes apoptotic cell death during
PDT. Previously, our laboratory showed that photosensitizers that localize to lysosomes
are more effective in killing cancer cells than ones directed to mitochondria after PDT.
Here, we investigated the interactions between lysosomes and mitochondria in promoting
the efficiency of PDT cell killing efficiency_ Three head and neck cancer cell lines
(UMSCCl, UMSCC14A and UMSCC22A) were exposed to Pc 4-PDT. The 3 cell lines
responded differently: UMSCG.l and UMSCC14A cells were more resistant, whereas
UMSCC22A cells were more sensitive to Pc 4-PDT.

In non-erythroid cells, the

mitochondrial iron transporter mitoferrin2 (Mfrn2) localizes on the mitochondrial inner
membrane and transports iron' from the cytosol into the mitochondria. PDT-sensitive cells
expressed higher Mfrn2 mRNA and protein levels compared to PDT-resistant cells. High
Mfrn2 expressing cells showed higher rates of mitochondrial Fe2+ uptake compared to
low Mfrn2 expressing cells. Bafilomycin, an inhibitor of the vacuolar proton pump of
lysosomes and endosomes that releases lysosomal iron to the cytosol, enhanced PDTinduced cell killing of both resistant and sensitive cells. Inhibition of the divalent metal
transporter 1 (DMTl) on lysosomal membranes by ferristatin markedly protected high
Mfrn2 expressing cells against bafilomycin-enhanced PDT toxicity, suggesting that iron
x

release after bafilomycin occurs via DMTI.

Iron chelators and the inhibitor of the

mitochondrial Ca2+ (and Fe 2+) uniporter, Ru360, protected against PDT plus bafilomycin
toxicity. Knockdown of Mfrn2 in UMSCC22A cells decreased the rate of mitochondrial
Fe2+ uptake and delayed PDT plus bafilomycin-induced mitochondrial depolarization and
cell killing.

Conversely, increased expression of Mfrn2 in low Mfrn2 expressing

UMSCCI cells increased PDT plus bafilomycin-induced killing.

Chloroquine, which

also releases iron from lysosomes, significantly delayed tumor regrowth ·in high Mfm2
expressing tumors after PDT.

Taken together, the data suggest that lysosomal iron

release and mitochondrial iron uptake through Mfrn2 act synergistically to induce PDTmediated and iron-dependent mitochondrial dysfunction and subsequent cell killing.
Furthermore, Mfm2 expression levels in tumors might be utilized as a biomarker
predicting response to PDT in head and nec~ cancers.
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Chapter 1

Review of Head and Neck Cancer,
Photodynamic Therapy, and
Iron Physiology and Pathophysiology

1

1.1. Head and Neck Cancer

1.1.1. Epidemiology and Etiology
Head and Neck Cancer (RNC) covers a broad spectrum of soft tissue malignant neoplasms of the tongue, lips, nasal and oropharyngeal cavities, paranasal sinuses, major and minor salivary glands, larynx, and the lymphatic tissues of the neck
(Fig. 1). It is the 6 th most common cancer worldwide and accounts for approximately
6% of all cases of cancers [1-3]. Each year, over 650,000 new cases are diagnosed
worldwide, and 350,000 patients die from this disease [3]. More than 90% of the
cancers are squamous cell origin from the epithelium of the mucous-lining membrane of the upper aerodigestive tract (UADT) [4], and therefore squamous cell carcinoma (SCC) represents the majority of head and neck cancers. Head and neck
cancers with adenocarcinoma origins from associated secretory glands are rare. Early stages (stage 1/11) of head and neck cancer have good prognosis after surgery or
radiotherapy, with 75% overall 5-year survival rate [5]. However, approximately 66%
of patients diagnosed with head and neck cancer are already in stages III and IV, for
which the prognosis is poor, and the overall 5-year survival rate is 35% [6, 7].
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Figure 1. Anatomic sites and subsites of the head and neck cancer. Approximate distribution of head and neck is 44% oral cavity, 31 % larynx and 25% of
pharynx. Adopted/rom CANCER MANAGEMENT: 13TH EDITION, March 25,
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Risk Factors
Head and neck cancer is strongly associated with environmental and lifestyle
risk factors. Tobacco (including smokeless), alcohol, poor diet, UV radiation, and
virus infection are the most important risk factors for head and neck cancers. Nearly
80% of head and neck cancers are tobacco and alcohol related [8]. More than 60 carcinogenic combustion products have been found in tobacco smoke, and therefore tobacco is a major risk factor for the susceptible epithelial mucous-lining membrane in
which head and neck squamous cell carcinoma arises. Oral and pharyngeal sites, as
well as the upper aerodigestive tract, are especially vulnerable to smoke insult.
Smoke contains carcinogenic materials like 4-(methylnitrosamino )-1-(3-pyridyl )-1butanone (NNK), N-nitrosonomicotine (NNN), and polycyclic aromatic hydrocarbons (PARs), which have been linked to UADT cancer through their activity producing DNA adducts [9]. In addition to

this~mutagenic

effect, tobacco also causes oxida-

tive stress to the exposed tissues through reactive oxygen species (ROS). ROS can
damage proteins, lipids, carbohydrates and DNA, which also results in mutation and
increases malignant transformation.
Alcohol promotes oncogenesis through increased permeability of cell membranes by damaging their phospholipid components to enhance the penetration of
tobacco-containing carcinogens across oral mucosa. Impaired DNA repair mechanisms activate carcinogens and decrease activity of the detoxification enzymes (glutathione-S-transferases and cytochrome P 450) in the liver [10, 11]. Some alcoholic
beverages

contain

.

.

carCInogenIc

impurities
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or

contaminants,

such

as

N-

nitrosodimethylamine [12], which is present in some beers and whisky and has been
linked to the increased risk of oral cancer. Thus, smoke and alcohol are the major
risk factors for head and neck cancer.
In Western Countries, dietary factors are estimated to account for 30% of all
cancers [13]. Poor diet has been reported as a significant risk factor for head and
neck cancer and is second to tobacco and alcohol as a cause of oral cancer worldwide
[14]. According to the World Health Organization (WHO), dietary deficiencies or
imbalances contribute to approximately 15% oropharyngeal cancers [15]. Since oxidative stress is one of the major factors to induce transformation of normal cells into
malignant cells, vitamins with antioxidant activity, such as vitamins A, C, and E, and
selenium have been reported to provide protection against most epithelial cancers by
reducing the generation of free radicals that can cause DNA mutations and cellular
membrane peroxidation [16-18]. Additionally, micronutrient diets also protect
against cell malignancy by modulating cellular carcinogen metabolism, maintaining
proper cell differentiation and immune function, and inhibiting cell proliferation and
oncogene expression [19]. Therefore, a diet with excess preserved food (e.g., nitrates
and nitrites) that increases cellular oxidative stress or a diet lacking in fresh fruits
and vegetables elevates the risk for head and neck cancer [20-22].

Prolonged exposure to sunlight (e.g., UV light) increases the risk to develop lip
cancer [23]. People with outdoor occupations are particularly more susceptible to lip
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cancer. Radiation exposure has also been reported to increase the risk of thyroid cancer and has been associated with cancer of the salivary glands [24, 25].

The growing incidence of oropharyngeal cancer among younger head and neck
cancer patients is related to human papillomaviruses (HPVs) infection [26-30]. To
date, more than 200 different types of HPV s have been isolated and categorized into
different groups according to their infection sites (cutaneous or mucosal) or risk for
malignancy (high, intennediate, or low) [31, 32]. HPV s with low risk induce benign
hyperplasias, like papillomas or warts, whereas HPV s with high risk are strongly associated with malignancy and carcinogenesis [33]. People with HPV infection in oral
mucosa and showing HPV in the serum are at high risk for developing an oral squamous cell carcinoma (OSCC) [34-36].

For head and neck cancer, the HPV types of most concern are those capable of
infecting the epithelial mucosal lining of the aerodigestive tract. HPV 16 and HPV
18 are strongly associated with head and neck carcinogenesis, particularly of the oral
cavity and oropharynx (tonsil and tongue base) [37-39].

HPV-positive head and

neck cancers are different from HPV-negative tumors, both clinically and biologically [40, 41]. Interestingly, HPV -infected

osce patients tend to have better outcomes,

greater treatment responses, and less chance of relapse compared to those with HPVnegative head and neck cancers [42-44]. The response to treatment is linked to functional p53. Indeed, a decreased number of p5 3 mutations have been reported in HPV-

6

positive cancers [45-48]. In addition to HPV, Epstein-Barr virus (EBV) has been
strongly linked to nasopharyngeal carcinomas (NPC) [49, 50].

1.1.2. Pathogenesis
Head and neck squamous cell carcinoma results from successive accumulation
of somatic gene alterations in the squamous epithelial lining of the upper aerodigestive tract [51, 52]. The progression of head and neck cancer from nonnal histologic
features to hyperplasia, mild, moderate, and severe dysplasia, carcinoma in situ, invasive carcinoma, and metastasis is accompanied by multiple gene mutations and
gains and losses of chromosome functions [53]. Down-regulation of tumor suppressor proteins (p53., Rb., Notchl), up-regulation of oncogenic proteins (Epidennal
growth factor receptor [EGFR]), Phosphoinositide-3 kinase catalytic subunit
(PI3CA), c-Met ligands, or hepatocyte growth factors (HGF)) and chromosomal gain
and loss function on 3p14, 9p2l, 17p13, 8p, llq, l3q., l4q, 6p, 4q27, and 10q23 have
been observed in head and neck squamous pathogenesis (Fig. 2) [53-57].

In head and neck cancer, a loss of tumor suppressor gene activity has been frequently observed rather than a gain or activation of oncogene function. The somatic
TP 53 mutation represents 60-80% of head and neck cases [58-60]. Among head and
neck cancers, approximately 800/0 were HPV -negative, with a large proportion of
cases harboring the TP53 mutation, while 20% of HPV -positive cases had decreased
p53 levels but intact p53 function [57, 61]. This finding points to the important role
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of p53 in head and neck cancer therapy. At the same time, it makes a pharmacological treatment difficult, since regaining tumor suppressor gene function is more challenging than inhibiting oncogene activity.
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1.1.3. Treatment Modalities for Head and Neck Cancer

For head and neck cancer, traditional treatment options are surgery, radiotherapy, chemotherapy, and any combination of these therapies. Surgery is carried out
when the tumor is resectable, without organ function compromise, and the patient is
able to tolerate the surgical procedure. Surgery is generally recommended for patients with early stages (1/11) of head and neck cancer [62]. However, when the tumor
is not resectable or organ function loss is a concern, single modality radiation therapy may become an alternative treatment for early stage patients [62]. For patients
with advanced stages status (above III), surgery alone is considered only appropriate
in the absence of nodal spread. When patients present with nodal disease (N1-2),
multiple modalities are applied, with resection of the primary tumor by surgery followed by radiation therapy or chemoradiotherapy [62]. The goal of radiotherapy is to
intensify and focus the treatment dose in the cancerous area while saving the normal
tissue from radiation damage.
Single drugs cannot cure most

c~cers.

Therefore, chemotherapy is executed as

a combination with multiple drugs or combined with surgery and radiotherapy. Historically, first-line chemotherapy for recurrent and metastatic head and neck cancer
has been cisplatin [63]. Currently, however, the most frequently used chemotherapeutic drugs for head and neck cancer patients are platinum compounds (5fluorouracil, methotrexate, and cetuximab). Chemotherapy is often combined with
radiotherapy. Radiotherapy with platinum-based chemotherapy is a common cancer
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treatment regimen and has become an alternative treatment modality for surgery in
the treatment of locoregional advanced head and neck cancer [64-66].

Molecular Targeted Therapies
Molecular targeted therapies have been developed to maXImIze delivery of
therapeutic doses to the cancer cells while minimizing side effects and toxicity in the
normal cells. Epidermal growth factor receptor (EGFR) is frequently up-regulated in
head and neck cancers. Thus, cetuximab, which is an anti-EGFR monoclonal antibody (mAb) and targets EGFR, has been effective against unresectable laryngeal,
oropharyngeal, or hypopharyngeal carcinomas when combined with platinum-based
chemotherapy or radiotherapy [64-67].

Genetic events frequently observed in head and neck cancer are tumor suppressor gene (e.g., p53, p16, p21) loss of function and chromosome (e.g., 3p, 9p and 17p)
loss of heterozygosity [68]. Mutations of p53 have been found ranging from 40 to
70% in head and neck cancer, and 20% in the premalignant lesion areas [69, 70].
Mutation of p53 is associated with more aggressive cancer status, poor prognosis,
poor survival rate, and higher local recurrence in head and neck cancer patients [7173]. P53 regulates genes involved in cell cycle control and apoptosis. Head and
neck cancer patients with a long history of tobacco and alcohol use are more frequently found with a p53 mutation in their tumor samples. Most p53 mutations are

11

guanidine transversions thymidine mutations, with less extent of missense mutations
on exon 5 and 9.

Currently, there are three ways to restore wild type p53 function in cancer patients. The first is application of antagonists ofp53-negative regulators (e.g., murine
double minute 2) in patients with wild type p53 whose p53 function is limited by
these negative regulators [74]. The second is reactivation of mutated p53 by either
applying small molecules, an antibody (e.g., antibody 421), a heat shock protein (e.g.,
chaperone protein dnaK), or artificial high-affinity DNA-binding sequences ofp53 to
assist p53 refolding and rescue p53 's biological function. The third is exogenous
expression of wild type p53 in tumors by adenovirus-mediated gene therapy [75].
Data from clinical trials of Ad-p53 delivery to 445 patients with advanced squamous
cell carcinoma, lung cancer, colon cancer, and prostate cancer showed that Ad-p53
gene therapy was a safe and well-tolerated therapy [75]. Many clinical trials with
Ad-p53 are origoing on head and neck cancer patients [75].
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PhotodynamicTherapy (PDT)
PaTienT is diagnosed wiTh cancer
PhoToToxic drug is adminisTered.
AccumulaTes in Tumour Tissue

Drug is aCT ivaTed by ~
illuminaTion wiTh laser

Highly Toxic radicals
generaTed kill
Tumour cells

Figure 3. Photodynamic therapy simplified schematic which shows the three
major components of the PDT therapy: light, photosensitizer, and oxygen.
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1.2. Photodynamic Therapy
PDT is a US Food and Drug Administration (FOA)-approved, minimally invasive treatment modality that utilizes light in the presence of oxygen to activate photosensitizing agents to produce cell death (Fig. 3) [76]. Absorption of a photon activates the photosensitizer to an excited singlet state that can then undergo intersystem
crossing to the triplet state. The triplet transfers energy to molecular oxygen to generate singlet oxygen (102 ). This is referred to as a Type II photochemistry [77]. Oxidation-reduction reactions also occur to generate other reactive oxygen species (ROS)
[77]. PDT has various clinical applications; among these, PDT as a treatment of cancer is especially promising and attractive.

PDT has many advantages. The photosensitizers do not accumulate in the nuclei and therefore do not induce DNA damage or mutagenesis or generate resistance
to the therapy, which commonly occurs after chemotherapy or radiotherapy. PDT
can be applied as a combination therapy either prior to or after other treatments (e.g.,
chemotherapy, radiation, surgery) without compromising the therapeutic effects of
those modalities. PDT is a non-invasive treatment modality, and treatment can be
repeated on patients. Currently, PDT is under intensive investigation for treatment of
various forms of cancers [77-87].

14

1.2.1. Photosensitizers
Photo sensitizers are the key components in PDT. The ideal photosensitizer
would have the following characteristics. It would be present as a pure single compound of known composition and stable at the room temperature. It would not induce dark toxicity and would have more rapid clearance from normal cells and tissues than tumor cells. It would not yield any toxic metabolites. Its absorption wavelength would span from red to deep red (600-800 nm). The longer the absorption
wavelength, the deeper the photosensitizer can penetrate into tissues. Therefore, photo sensitizers with absorption peaks at longer wavelengths are more favorable for
clinical applications. However, above 800 nm, the energy is insufficient to excite oxygen to generate 102 and yield PDT's intended effect. Thus, the ideal absorption
wavelength for the photo sensitizers is 600-800 nm.

Photo sensitizers can be administered through numerous routes (e.g., oral, intravenous, topical, intratumoral, inhalational). The ideal photosensitizer would have
a good pharmacokinetic profile, high quantum yield to produce 102 , inexpensive, and
would not target the nucleus as a possible mutagenic agent [77, 88, 89]. Photosensitizers are generally categorized into porphyrin or non-porphyrin groups, as show in
(Fig. 4 A-B) [88]. Porphyrin-derived photo sensitizers are further classified into first,
second, and third generation based on their improved characteristics and modifications. Most photo sensitizers used in cancer therapy are porphyrin-related, meaning
they have a hetero-cyclic ring and tetrapyrrole structure that resembles that of the
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protoporphyrin present in chlorophyll, hemoglobin, or hematoporphyrin (Fig. 5) [77].
Structures of porphyrin molecules have a 22n electron system which confers a long
wavelength absorption [88].

Porphyrin Derived Photosensitizers

First Generation Photosensitizers
The first clinically applied photosensitizer for cancer treatment was a water
soluble, porphyrin-derived molecule named hematoporphyrin derivative (HPD),
which was later called Photofrin™ (porfimer sodium) [90]. Although Photofrin is
one of the most widely used photo sensitizers, it has some unfavorable characteristics,
such as low cellular uptake, low molar.: extinction coefficient (1170 M- 1 em-I) that
results in a poor therapeutic effect, arid long-lasting photosensitivity caused by a long
half-life of 452 h [88,91]. Because of these limitations, second generation porphyrin-derived photo sensitizes have been developed.
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Second Generation Photo sensitizers

The second generation photo sensitizers attempted to improve PDT efficacy
and reduce unfavorable characteristics of the first generation photo sensitizers. Second generation photo sensitizers have several advantages: 1) reduced skin photosensitization after treatment; 2) absorption at longer wavelength to facilitate deeper tissue penetration; and 3) increased cellular uptake. Phthalocyanine (Pc), chlorin, protoporphyrin IX, and foscan are currently under intensive investigation for cancer
treatment (Fig. 4 and 5) [81, 92-95].

The Phthalocyanine (Fig. 5i) family, derived from porphyrin as a second generation photosensitizer, has high quantum yield to generate 102 and has a strong absorption peak at 670-770 nm. This long wavelength allows penetration into deep tissue. Pc has a central metal atom (M), either zinc, aluminum, or silicon, which stabilizes the Pc structure and also yields long-lived triplet state 102 , enhancing PDT's
effect (Fig. 5i) [96].

Phthalocyanine 4 (Pc 4), one of the most studied phthalocyanines, localizes to
the membranes of the mitochondria, endoplasmic reticulum and Golgi and has
shown promising in vitro and in vivo results [92, 97, 98]. Pc 4 has a dimethylaminopropyl siloxy ligand on its central silicon. It is a hydrophobic molecule and
binds to lipoproteins and serum albumin, which delivers it into cells [99]. Pc 4 causes mitochondria-mediated apoptotic cell death [92, 97]. A Phase I clinical trial of Pc
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4-PDT has been completed for cutaneous neoplasms [98], and it is currently in a
Phase I trial for psoriasis. In addition, over 250 analogs of Pc 4 have been synthesized, some of which have been further investigated for their potential in PDT [100102]. Results showed that Pc 4 analogs with two axial ligands increased Pc monomerization, which improved Pc cellular uptake. Pc 4 analogs such as Pc 181, with
hydroxylated ligands, preferentially localize to lysosomes. Pc 181 was found to be
more effective in killing cancer cells than Pc 4 from in vitro study [97].

Foscan (Fig. 5c) is a single pure chlorine derivative that absorbs light at 652
nm. It has a long plasma half-life (45-65 h) and is a very potent photosensitizer [88].
Due to its superior photophysical properties and high 102 yield, a small drug dose
(0.1 mg/kg) and light intensity (10 J/cm 2 ) are needed to obtain a robust PDT effect
[91]. Currently, foscan has been approv£d in Europe to treat head and neck cancer.
Foscan accumulates preferentially in brain tumors, with the ratio of tumor to normal
cells as 100:1; which makes foscan a superior cancer targeting photosensitizer [103105]. A nonrandomized phase II study'offoscan-PDT on lip cancer showed complete
response, which is just as good as patients treated with surgery or radiotherapy [106].
Presently, foscan is one of the photo sensitizers that have been intensively applied to
head and neck cancer because of its high efficacy. However, a long plasma half-life
offoscan causes prolonged photosensitivity.
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Protoporphyrin IX (Fig. 5g) is a second generation porphyrin derived photosensitizer that is activated by light to initiate the PDT reaction. Protoporphyrin IX is
converted from its hydrophobic precursor 5 aminolevulinic acid (5-ALA), which is
involved in heme biosynthesis (Fig. 6). After conversion of 5-ALA into protoporphyrin IX by mitochondrial enzymes, it can be activated by light at 630 nm to cause a
PDT effect [107]. Since protoporphyrin IX is localized to mitochondria, the main
PDT effect occurs on mitochondria. Tumor cells tend to accumulate 2 fold more on
protoporphyrin IX-treated as compared to normal cells. [88]. Thus, increased accumulation of protoporphyrin IX can be an advantage for cancer therapy. Protoporphyrin IX has been applied with PDT to treat superficial basal and in situ squamous cell
carcinoma and actinic keratosis [108, 109].

Researchers are trying to improve 1Jrotoporphyrin IX PDT efficacy by increasing ALA metabolism into protoporphyrin IX or decreasing protoporphyrin IX conversion into heme. One way to enhance protoporphyrin IX-PDT is to apply iron chelators, which block incorporation of iron into protoporphyrin IX and heme biosynthesis, resulting in protoporphyrin IX accumulation [110].

Third Generation Photosensitizers
Third generation porphyrin-derived photo sensitizers have been improved by
increased tumor targeting specificity, photosensitizer stability, cellular uptake, and
efficacy by formulating photo sensitizers with liposomes, nanoparticles, and poly-
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mers [88].

Tumor oncogenes such as EGFR have been utilized for micelle-

formulated nanoparticles Pc 4 with GEll peptide ligands to enhance photosensitizer
delivery to EGFR-overexpressed cancer cells [111]. In addition, poly (ethylene glycol)-poly (e-caprolactone}-poly (ethylene glycol) (PEG-PCL) micelle nanoparticles
have been applied to improve the delivery of the highly hydrophobic photosensitizer
Pc 4 into cells and increase its bio-distribution. Pc 4 PEG-PCL shows intracellular
uptake and improved cytotoxicity [112].

Non-Porphyrin Photosensitizers

Non-porphyrin photo sensitizers have been considerably less studied due to a
lack of encouraging clinical results [88]. Most of the non-porphyrin photo sensitizers
are cationic dyes that selectively accumulate into mitochondria with negative membrane potential [88]. Hypericin, which has shown good tumor selectivity and in vitro
efficacy, is considered as a potential candidate for the clinical application, but it has
not been successful in clinical trials thus far [88].

Results from several institutions have shown that PDT can successfully treat
early carcinomas in the head and neck regions, including the oral cavity, pharynx,
and larynx, and at the same time preserve the organs and their vital functions of
speech and swallowing [113, 114]. In one small randomized clinical trial which
compared patients treated with porfimer sodium-PDT (foscan-PDT) to patients treat-
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ed with chemotherapy (5-FU and cisplatin) In nasopharyngeal carCInoma, PDT
demonstrated better clinical outcomes.

In a 15 year accumulating clinical research with more than 300 patients who
were treated with the porfimer sodium-PDT with a single PDT procedure, showed
that in the laryngeal carcinoma group (133 patients) after average 8 year follow up,
the 5 year cure rate was 90%, and in the oral cavity group (138 patients), after up to
211 months follow up, the 5 year cure rate was 100% with a totally complete pathological and clinical response in patients [115]. The protocol used in this study was
following of 2.0 mg/kg of porfimer sodium IV administration for 48 h, then irradiated with 630 nm of light from a neodymium yttrium aluminum garnet (Nd:YAG)
pumped dye laser with 50-75 J/cm2 fluences for oral cavity, nasopharyngeal, and 80
J/cm2 fluences for laryngeal tumors.

Currently, over 500 head and neck cancer patients with early stage oral cavity,
larynx, pharynx, and nasopharynx lesions were treated with porfimer sodium-PDT
worldwide and showed similar success [116-118]. From these studies, only a small
number of patients experienced recurrence and were treated either with surgery or
repeated PDT. The only complaints from these patients were photosensitivity of skin
and local pain, which can be controlled with oral analgesics.
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In addition to the porfimer sodium-based PDT, 5-ALA and foscan have also
been applied to treat head and neck cancers. Currently, foscan is the most wildly applied second generation photosensitizer used in head and neck cancer treatment and
has shown impressive results. In a study of foscan-treated head and neck cancer patients (n=27), results showed the cure rates for stage I were 85%, with a 38% rate for
stages II and III [119]. In another foscan based PDT treatment with patients who had
been treated unsuccessfully with traditional cancer therapies or were unable to go
through the traditional therapies, results from 96 h post-foscan PDT found that 430/0
of the lesions showed 100% tumor mass reduction, and 57% of lesions showed at
least a 50% tumor mass reduction [120]. However, researchers pointed out that,
when the total surface area of the tumor could be illuminated or the tumor depth was
less than 1 em to allow light penetration into the whole tumor, treatment success significantly increased.

,

.-

For 5-ALA-based PDT treatment In head and neck cancers, fewer reports
showed less successful rates in terms of clinical outcome compared to either the
porfimer sodium or the foscan [121, 122]. In conclusion, results from current phases
1/11 head and neck cancer trials strongly demonstrated that PDT is an effective cancer
treatment modality either as primary or alternative therapy. In addition, patients who
received PDT treatment also benefitted from organ preservation, a lack of systemic
toxicity, and better quality of life.
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Subcellular Localization

Subcellular localization of the photosensitizer is a main factor to determine site
of 102 generation and initial photodamage [123]. Many organelles (e.g., mitochondria, lysosomes, endoplasmic reticulum, Golgi apparatus, and plasma membrane)
have been studied as cellular targets for photosensitizers [124]. The important factors determining cellular localization of the photosensitizer are 1) net ionic charge of
the photosensitizer that can range from (-4) anionic to (+4) cationic; 2) hydrophobicity of the photosensitizer; and 3) degree of asymmetry of the photosensitizer. Hydrophobic photo sensitizers with net charge less than two negative charges

«

-2)

freely diffuse across the plasma membrane and then redistribute to intracellular
membranes of other organelles, resulting in high cellular uptake. Less hydrophobic
photosensitizers with less than two negative charges are too polar to diffuse across
the plasma membrane, and therefore they are taken up by cells through endocytosis/pinocytosis [89].

1.2.2. Photochemistry of PDT

Light absorption and energy transfer are the two maIn photochemical/photophysical events during PDT (Fig. 7). In the ground state, the photosensitizer
has two electrons with opposite spin in an energy most favorable low molecular orbital as the singlet state. When the photosensitizer is activated by light, one electron
is boosted into a higher energy orbit but maintains its original spin direction. This
state is unstable and emits extra energy as either fluorescence or heat. Alternatively,
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the excited photosensitizer may undergo intersystem crossing to form a more stable
high energy state that has one electron inverted to form a parallel spin of electron
conformation [125].

The triplet state of a photosensitizer can transfer its energy to other molecules
through either type I or type II reactions (Fig. 7). Most PSs are believed to undergo
type II reactions during PDT [77]. In a type II reaction, the triplet state of the activated PS transfers its high energy to the adjacent molecular oxygen (0 2) to form highly
reactive 102 . Alternatively, in a type I reaction, the triplet state of the activated photo sensitizer transfers its high energy to the substrates and organic molecules other
than 02 through proton or electron transfer and forms a radical anion or cation, respectively. These radicals can further interact with O 2 to generate ROS, such as superoxide anion radical (0 2--), hydrogen peroxide (H202), and a hydroxyl radical
(OH·). The type of photosensitizer, biological substrates, and the level of O 2 all detennine what 'type of reaction occurs during PDT [126]. Since 102 and ROS (except
,

H202) are highly reactive and short lived, they interact with biomolecules on the sites

where ROS are formed. Thus, PDT's effects occur in close proximity to the photosensitizer.
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1.2.3. Light Sources and Light Delivery
In PDT, light is also a crucial factor to detennine outcomes since precise light
delivery can activate the PS in tumor areas and selectively destroy the cancer. Inside
the tissue, light can be either absorbed or scattered. Therefore, one way to improve
PDT efficacy is to focus the light on targeted areas. Red and infrared light has the
deepest penetration (up to 1 cm into tissue) whereas blue light penetrates least efficiently into tissue (Fig. 8) [127]. The light region between 600 and 1200 run is often
called the optical window of the tissue [77]. Above 800 run, however, the energy of
the light is insufficient to activate PS and cause a PDT response.

No single light source is ideal for all PDT applications. Depending on the photosensitizer used, a light source with specific wavelength needs to be applied to obtain maximal photosensitizer activation: The efficacy of the PDT is dependent on
complex dosimetry, which is determined by total light dose, total light exposure time,
and the mode in which light is delivered (e.g., single or fractionated mode). Both lasers and incandescent light sources are applied for PDT and show equivalent efficacies [128, 129]. The diode laser is the most commonly used PDT light source, but
some researchers have used LED as an alternative source. Since laser light is coherent, the laser is coupled with a fiber to transfer consistent and stable light deep into
tissue maximally [130].
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1.2.4. Role of Oxygen in Photodynamic Therapy
Besides the photosensitizer and light, oxygen is an important factor in determining PDT outcomes. Using PDT in solid tumors is challenging. Decreased oxygen tension deep in poorly vascularized tumors can result in decreased formation of
102 and

other ROS, thereby diminishing the therapeutic effect.

102

generation during

PDT treatment can induce local hypoxia in tissue [131]. In order to overcome these
challenges and improve PDT efficacy in hypoxic solid tumors, several strategies
have been developed, such as using fractionating light for irradiation and allowing
tissue reoxygenation during intervals between PDT treatments [132]. PDT has also
been administered to patients in hyperbaric oxygen (HBO) environments to provide a
continuous oxygen supply. Hyperoxygenation of tissue has successfully extended the
survival period in patients with esophageal carcinomas [133, 134] although this application requires a pressurized chamben, which is not widely available. Strategies to
overcome these oxygen-related PDT limitations are still under investigation.

1.2.5. Mechanisms of PDT-Mediated Cytotoxicity
PDT is a cancer therapy modality that causes cytotoxicity by direct cell killing
through apoptosis, necrosis, and autophagy pathways. PDT can also target tumor
vasculature to block nutrient supply in tumors and thus inhibit tumor survival. PDT
can also boost host immunity, which helps to combat cancer [77]. Mechanisms of
PDT induced cancer cell death are addressed below.
1.2.5.1. Direct Cytotoxicity
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Due to the very short half-life of the

102

(approximately 10-320 nanosec), it can

only interact with biomolecules within 10 nm to 55 nm after its generation [135].
Therefore, cellular sub-organelle localization of photo sensitizers plays an important
role in determining mechanisms involved in photodamage-caused cell death. PDT
can cause direct cytotoxicity through three main cell death pathways: apoptosis, necrasis, and autophagy, among which apoptosis is generally the major cell death
pathway involved after photosenistizer-induced photodamage [136]. In general, it is
commonly agreed that lower doses of PDT lead to more apoptotic cell death while
higher doses of PDT tend to cause more necrotic cell death proportionately [137].
However, cell death pathways that occur are determined by cell type, cellular localization of photosensitizer, PDT dose (photosensitizer concentration, light dosimety),
and protocols applied.

Photo sensitizers mainly localized to the mitochondria, such as Pc 4 [92], cause
cell death though the mitochondria-mediated apoptotic cell death pathway. After Pc
4 is irradiated by light at the red wavelengths, it initiates mitochondrial depolarization, followed by cytochrome c release, and caspase 3/7 activation to cause apoptotic
cell death [160]. Researchers have reported that, for mitochondria localized photosensitizers, Bcl-2 dissipation is the initiation step to trigger mitochondrial outer
membrane permeabilization and mitochondrial membrane potential loss, which in
tum leads to downstream caspase 3/7 activation and eventually apoptotic cell death
[138-140].
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In addition to apoptosis, phototoxicity can lead to cell death through nonapoptotic pathways, which include autophagic and necrotic pathways [141]. Generally, in
the event of caspase-deficient conditions such as caspase genetic knockout or caspase inhibitor administration, cells delay their response to phototoxicity and shift to
necrosis [142]. Although the molecular mechanisms of necrosis are still not well understood, researchers have reported some events that lead to necrosis, including receptor interacting protein 1 (RIPl) activation, lysosomal damage, block of ATP synthesis, intracellular Ca2+ overload, and an excess of mitochondrial ROS generation
[143, 144].

Autophagy occurs through a lysosome mediated cellular pathway to recycle
cellular components. Various stress siggals can induce autophagy, including oxidative stress [145]. Researchers have reported that some photosensitizers induce autophagy during the PDT process, although the role of the autophagy process could be
either cytoprotective or pro-death [145]. Currently, a general conclusion from all the
present findings is that autophagy induces cell death and plays a pro-death role under
situations when the apoptosis pathway is defective or when the autophagy recycle
mechanism is impaired due to overwhelming stress conditions [146, 147]. Alternatively, autophagy plays a pro survival role and rescues the cells when the cells are
under low stress conditions (low-dose PDT) where autophagy can repair cell damage
[148]. Similar to necrosis, when cells are under stress but the apoptosis pathway is
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inhibited due to caspase deficiency, autophagy can also serve as an alternative cell
death pathway.

Studies from Bax-deficient DU145 human prostate cancer cells and Bax
knock-out HCTl16 human colon cancer cells showed that, although these cells have
deficient apoptosis pathways, cells still retain a similar degree of cell killing under
Pc 4-PDT treatment [203, 204]. These findings suggest the possibility of another
bax-independent cell death pathway. In addition, researchers found vacuole formation in these cells under electron microscopy and the conversion ofLC3-I to LC3II after Pc 4-PDT treatment [149]. After applying the autophagy blockers 3methyladenine and wortmannin, which inhibit Pc 4-PDT-induced cell death in these
bax deficient cells, researchers concluded that cells deficient of bax underwent autophagy-mediated cell death [150].

Additio'nally, it has also been reported that PDT induces both autophagy and
apoptosis concurrently using the CPO photosensitizer in murine leukemia L1210
cells. These photodmaged cells showed both apoptotic and autophagic characteristics,
including chromatin condensation, mitochondrial depolarization, phagolysosome
formation, and conversion ofLC3-1 to LC3-II [149].
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1.2.5.2. Vascular Effects
Since blood supply supports tumor growth, one strategy for cancer therapy is
to target tumor vasculature with anti-angiogenic agents that inhibit neovascularization in solid tumors. Besides causing cytotoxic effects, PDT concurrently may cause
vascular damage that leads to ischemic cell death in tumors [151, 152]. These findings suggest that targeting tumor vasculature provides another mechanism to treat
solid tumors. Since photo sensitizers are bound to cellular lipoproteins (high-density
lipoprotein [HDL] and low-density lipoprotein [LDL]) and serum proteins (e.g., alburnins) to be carried into cells, endothelial cells that express receptors for serum
proteins and lipoproteins are primary targets for vascular approaches to PDT [153].

Typically, PDT procedures with shorter photosensitizer-light intervals restrict
photo sensitizers in the blood circulatioll and accumulate in endothelial cells or are
bound to vessel walls to cause vascular targeting effects whereas longer photosensitizer -light waiting periods following PS administration lead to cellular organelle dis-

.

tribution of the photo sensitizers and induce more tumor cell damage. PDT with short
photosensitizer-light intervals result in damage to the endothelial cells through loss
of tight junctions between cells and leads to blood cell adherence to vessel walls.
This damage induces the formation of thrombogenic sites with physiological cascade
of reactions including platelet aggregation, vasoactive molecules release, leukocyte
adhesion, increased vascular permeability and vessel constriction. Vasculaturetargeting PDT causes microvascular collapse, blood flow stasis, and tissue hemor-
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rhage that eventually leads to persistent post-PDT tumor hypoxia and nutrient deficiency, resulting in long-tenn tumor control [154, 155].

1.2.5.3. Immune Responses
PDT frequently triggers a strong acute inflammatory reaction as localized
edema, which is recognized by the host as an acute trauma. This recognition launches an acute inflammatory response as a protective action to remove damaged cells in
affected sites and promote local healing to restore tissue function, integrity, and cellular homeostasis [156]. PDT-provoked inflammation increases the penneability of
the tumor vasculature, which induces inflammatory cells (e.g., neutrophils, monocytes and macrophages) to invade the affected areas rapidly [156,157]. Subsequently,
dead and injured cells and PDT-damaged vasculature that forms occlusions are eliminated by inflammatory cells. Inhibition or depletion of the activity of these inflammatory cells as well as their regulatory cytokines interleukin (IL)-1 J3 and IL-6 reduce
PDT efficacy' [158-161]. In contrast, diminishing the anti-inflammatory cytokines
such as IL-IO and transforming growth factor-J3 (TGF-J3) significantly improves PDT
effects [156]. Increased CD8+ levels, T cell activation, and tumor infiltration have
also been linked to PDT efficacy [162, 163]. Therefore, effort has been focused on
mechanistic studies to potentiate CD8+ and T cell activation.
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1.2.6. Combination of PDT with Other Therapies

Most cancers are not curable through treatment with single drugs. This limitation applies to PDT as well. Thus, combining PDT with other modalities to improve
the therapeutic index has received much interest. In general, therapies with different
mechanisms or targets can be combined together to achieve either additive or synergistic effects.

PDT can be safely combined with other cancer therapy modalities

without compromising therapeutic outcomes or inducing cross-resistance between
the therapies [164]. PDT has been successfully combined with surgery, radiotherapy,
and chemotherapy [165-167]. The purpose of PDT in combination therapy is either
to further sensitize tumor cells and enhance overall tumor killing effects or to maintain therapeutic effects but significantly reduce systematic toxicity or adverse side
effects by reducing the treatment dose of other therapy. PDT can be combined with
other mechanism-driven drugs or modalities with further enhancement of therapeutic
outcomes.

PDT has been combined with radiotherapy [167], chemotherapeutic

drugs such as platinum compounds and proteasome inhibitors [168], and overexpressed EGFR and folic acid receptor '[169].

PDT has also been combined with erythropoietin (EPO) and hyperbaric oxygen to increase oxygen in the tumor cells [170]. In addition, two different mechanism-driven photo sensitizers can be combined in PDT treatment to obtain better outcomes [171]. Combination PDT with other therapy enhances treatment efficacy
without affecting normal cells and tissues, and in some cases can also reduce system-
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ic toxicity. Therefore, PDT combination therapy is of great interest and is a major
focus in clinical research.

,
~

38

1.3. Iron Physiology and Pathophysiology

Iron is essential for the biological system. In eukaryotic cells, iron participates
in several cellular processes, including oxygen transport, oxidative phosphorylation,
DNA biosynthesis, and xenobiotic metabolism [172]. In addition, iron is a constitutive part of physiologically important proteins, such as hemoglobin, cytochromes,
oxygenases, flavoproteins, and redoxins [173].

Iron exists either in reduced ferrous (Fe2+) or oxidized ferric (Fe 3+) form and
recycles between these two forms based on environmental conditions [174]. Depending on its oxidative status, iron is utilized by biological systems and integrated into
vital biologic processes that require transfers of electrons (e.g., respiration and oxidative phosphorylation processes) [175, 176]. Inside the cytoplasm, iron mainly exists
in Fe 2+, which is very active and rapidly reacts with 02 to form ROS. Especially
when Fe2 + interacts with H 2 0 2 , it ,generates highly reactive and toxic OH- through the
Fenton reaction to damage macromolecules, including DNA, lipid membranes, and
proteins [1 77]. Therefore, in the biological system, free iron levels are regulated in a
tightly controlled manner. Iron is always carried with proteins or iron transporters to
reduce the level of free redox-active iron and prevent cell damage and toxicity.

Considering the important biological role of iron, either iron overload or iron
deficiency causes dysregulation of biological systems and damages the organism.
Iron deficiency decreases heme synthesis and disturbs iron-regulated biological reac-
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tions, thus leading to decreased cell growth and proliferation, hypoxia, and even cell
death [178]. To maintain erythropoiesis and other iron-mediated vital cellular functions, 25 mg of iron is needed for daily use. However, dietary uptake of iron from
intestinal sources only provides 1 to 2 mg of iron supply [179]. Therefore, other cellular mechanisms of iron regulation, such as iron release from the cellular iron storage protein, ferritin or recycling of iron from iron-containing biomolecules through
the lysosome-mediated autophagy process, are extremely important and tightly regulated to provide iron needed for the biological systems [180].

Conversely, an excess of iron in biological systems leads to oxidative stress
and damages biomolecules that harm the organism. Prolonged oxidative stress to
biological systems causes inflammation, dysregulated cellular signaling pathways,
and various pathogeneses, including neurodegenerative diseases (e.g., Alzheimer's,
Parkinson's and Huntington's diseases and Friedreich's ataxia) and cancer [181-185].
Increased physiological iron levels have also been reported to be associated with infection [186, 187].

The amount of total body iron in a healthy human being is about 50 mg/kg.
This iron is derived from hemoglobin in erythrocytes and myoglobin in muscle cells
[179, 188]. Humans lack mechanisms to eliminate iron, except through loss of hemoglobin during bleeding or defecation of apoptotic enterocytes and macrophages.
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Since iron is important but dangerous at high or low levels, iron uptake and regulation is strictly controlled.

1.3.1. Cellular Iron Regulation
Following the release of iron from enterocytes and macrophages into the
bloodstream, iron binds to transferrin (Tf), which is a plasma glycoprotein with two
high affinity iron binding sites [189]. The fact that free iron binds to transferrin immediately after its release into the bloodstream prevents potential iron-induced toxicity in circulation. Fe3 + forms a complex with transferrin, which binds to transferrin
receptor 1 (TfR1) for receptor-mediated endocytosis, resulting in iron delivery to en-

dosomes/lysosomes [190]. In acidic late endosomes, Fe 3+ is released from the transferrin and transferrin receptor complex; it is converted to Fe 2+ by the enzyme ferrireductase, localized on the endosomal membrane. Fe 2+ is then transported out of lysosomes through the divalent metal,transporter 1 (DMT1) to form the labile or chelatable iron pool in the cytosol [191]. This iron is highly redox active and is distributed

.

to several cellular destinations for storage or usage (Fig. 9). Cytosolic iron can be
transported to ferritin, a cellular protein that sequesters and stores excess cytosolic
free iron within cells to avoid iron-mediated ROS generation and cellular damage.
Ferritin consists of heavy chain and light chain subunits, among which heavy chain
has the ferroxidase activity to convert Fe 2+ into Fe3+ and stores the whole complex as
a ferric oxohydroxide mineral [192]. In addition to its location in the cytosol, ferritin
is also found in the nucleus and mitochondria [193]. In addition, iron in the labile
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iron pool can also be distributed for cellular usage (ex: nucleus for DNA synthesis)
or be further transported to mitochondria through mitochondrial iron transporters (ex:
mitoferrins) to support iron-sulfur, heme, and iron-containing enzyme synthesis in
the mitochondria [194].
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For cellular iron export, the iron exporter ferroportin mediates Fe 2+ efflux from
enterocytes and macrophages into the plasma to maintain systemic iron homoeostasis.
This process is negatively regulated by a liver-derived peptide hormone hepcidin,
which is excreted from the liver into circulation and interacts with the ferroportin in
response to high intracellular iron level by promoting ferroportin phosphorylation,
internalization, and endocytosis degradation [195].

In addition to iron uptake and export, intracellular iron levels are also regulated
by the iron regulatory proteins 1 and 2 (IRP1 and IRP2) to maintain the balance of
cellular iron homeostasis [194]. IRPs act as cellular iron sensors to detect the changes in cellular iron level and interact with iron-responsive elements (IREs) to regulate
iron-related protein synthesis, including TfR1, DMT1, ferritin, mitochondrial aconitase, and 5-aminolevulinate synthase at the translational level [196, 197]. Cellular
iron-regulated proteins that are involved in iron uptake, storage, transport and metabolism are all under control of the IRPs and IREs in response to the cellular iron
,

condition. When cellular labile iron levels are decreased, the IRPs bind to ironresponse elements (IREs) within the 5'-untranslated region (5'-UTR) of ferritin
mRNA to inhibit the initiation of ferritin protein translation and down-regulates its
expression. Simultaneously, IRPs bind to IREs within the 3'-UTR of the TfR1 to
stabilize and protect its mRNA from being cleaved and degraded by the endonucleolytic enzymes and thus increase the expression of the TfR1 to restore cytosolic iron
levels. Conversely, cytosolic labile iron levels are increased, IRPs bind to IREs with-
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in the 5' -UTR of TtR 1 and 3' -UTR of ferritin to reduce the free iron uptake and facilitate the iron being stored into ferritin to decrease the cellular iron levels and restore iron homeostasis.

Mitochondrial Iron Regulation

Cellular iron homeostasis is maintained through the interplay among cytosolic,
mitochondrial, and lysosomal environments [180]. After Fe 2+ is released from endosomes into the cytosol through the DMTI to form the labile iron pool, Fe 2+ can be
transported into mitochondria through the mitochondrial iron transporters to supply
the iron needed for mitochondrial heme and iron-sulfur cluster synthesis or iron storage in mitochondrial ferritin.

Although the mechanism of mitodhondrial iron regulation is not yet well characterized, two proteins on the mitochondrial inner membrane have been identified
that participate in mitochondrial iron uptake: mitoferrin 1 (Mfml) and mitoferrin 2

.
(Mfrn2). Mfml expresses in erythroid cells whereas Mfrn2 expresses in nonerythroid cells [198, 199]. Mfml has been reported to increase its half-life during
erythropoiesis but the half-life of Mfrn2 remains the same in developing erythroid
cells [199]. Mfrn2 has three isoforms, which include a full length and two truncated
forms (Fig. 10). Although all three isoforms of the Mfrn2 [200] are able to localize to
mitochondria, so far all the functional studies of Mfm2 are based on the full length
isoform, considered the canonical isoform.
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1.4 Aim and Outline of the Project

The aim of this project is to study a mechanism based strategy to enhance the
efficacy of photodynamic therapy. In this project, we used the photosensitizer Pc 4.
Pc 4 has recently completed a Phase I clinical trial for cutaneous neoplasms and is
currently in a Phase I trial for psoriasis. Head and neck cancer is a disease model
which has been effectively treated with PDT using other photo sensitizers such as
foscan and porfimer sodium. Our aim was to determine how lysosomes contribute to
PDT induced by the mitochondria-targeted photosensitizer Pc 4. Specifically, we focused on the role of lysosomal iron in PDT's mechanism.
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Chapter 2

Role of Iron in Pc 4-PDT-Treated Head and Neck Cancer Cell Lines

48

Hypothesis
Iron released from lysosomes enhances mitochondria-mediated cell killing during Pc
4-PDT.

Introduction
Head and neck squamous cell carcinomas (HNSCC) rank as the 6 th most common cancers worldwide and lead to 350,000 deaths each year [3]. Despite advances
in treatment, 5-year survival of patients with HNSCC has not significantly iIp.proved
over the past several decades. First-line treatments are surgery, radiation, chemotherapy, and a combination of these modalities. However, many patients develop chemoand radioresistance, and only 50-60% of the patients treated with radiation and
chemotherapy are cured of their disease. Surgery is not an attractive mode of treatment since disfigurement dramatically affects quality of life. Therefore, better treatment modalities are needed to combat this devastating disease.

PDT is an FDA-approved, minimally invasive treatment modality that utilizes
light in the presence of oxygen to activate photosensitizing agents and produce cell
death. Currently, PDT has been shown to successfully treat early stages of HNSCC
in the oral cavity, pharynx, and larynx [115-120]. Because the photo sensitizers used
in PDT do not target the nucleus but other cellular organelles (e.g., mitochondria,
lysosomes, ER, plasma membrane), PDT does not cause mutagenic or carcinogenic
effects [77]. Together with its tumor selectivity and lack of systemic toxicity, PDT
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can be repeatedly used to treat patients to achieve maximal therapeutic effects. In
addition, PDT is a non-invasive therapy and can be combined with other traditional
therapies to maximize treatment outcomes, making it a very promising cancer treatment modality [77, 114,201-203]

Phthalocyanine 4 (Pc 4) is a second generation phorphyrin-based photosensitizer used in PDT. Pc 4 has a strong absorption peak at 670 run wavelength, allowing for penetration deep into tissue and a high quantum yield which efficiently generates 102 . Our laboratory has previously shown that Pc 4 localizes to cellular membranes of the mitochondria, ER, and golgi and causes mitochondria-mediated apoptotic cell death [204]. Pc 4 is a potent photosensitizer and has been applied with
promising results for malignant and non-malignant treatments in vitro, in vivo, and
clinically. Including 43 cancer patients :.who had actinic keratoses, Bowen's disease,
squamous cell carcinoma, basal cell carcinoma, or mycosis fungoides, a recent phase
I clinical trial showed promising effects to induce apoptotic cell death without causing any safety or toxicity issues [98].

Studies from other groups have shown that bafilomycin, a proton pump
ATPase inhibitor, collapses the pH gradient of lysosomes and releases iron from lysosomes into the cytosol, causing iron accumulation in mitochondria [205]. In line
with this, our group showed that bafilomycin enhanced Pc 4-PDT killing in A431
epidermal carcinoma cells through lysosomal iron release to cause mitochondrial de-
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polarization and onset of apoptotic cell death [92]. These findings suggested the role
of lysosomal iron in mitochondria-mediated PDT cytotoxicity.

In this study, our aim was to determine how lysosomes contribute to PDT induced by mitochondria-targeted photo sensitizers such as Pc 4. Specifically, we focused on the role of lysosomal iron in PDT killing. In cells and tissues, two pools of
iron exist. The first pool is "non-chelatable" iron, which is sequestered in ferritin
and in structural components of proteins (e.g., heme, iron-sulfur complexes) and
cannot be removed by iron chelators like desferrioxamine (DFO). The second pool
is "chelatable" iron, which represents free iron and iron bound loosely to a wide variety of anionic intracellular molecules [205]. Chelatable iron is accessible to DFO
and other iron chelators. Chelatable iron and other transition metals, such as copper,
catalyze formation of highly reactive

hy~roxyl

radical (OH) from H 2 0 2 and O 2 -- and

damage DNA, proteins, and membranes [206].

Lysosomes are a source of rapidly mobilized chelatable iron that, when released into the cytosol, is rapidly taken up by mitochondria through the calcium uniporter [205]. Inside mitochondria, this iron is available to catalyze toxic ROS cascades. Therefore, we hypothesized that iron translocation from lysosomes to mitochondria would enhance PDT-induced cell killing with mitochondria-targeted photosensitizers.
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Materials and Methods

Cell Culture. Human head and neck squamous carcinoma cell lines (UMSCC 1,
UMSCC14 and UMSCC22A) were a gift from Or. Besim Ogretmen (Medical University of South Carolina). Human A431 epidermoid carcinoma cells were obtained
from the American Type Culture Collection.

Cells were cultured in Oulbecco's

Modified Eagle's Medium (OMEM) (Gibco) supplemented with 10% fetal bovine
serum (FBS) and penicillin/streptomycin (complete culture medium) in a humidified
37°C incubator at 5% C02/95% air.

Cellular Pc 4 Uptake. The phthalocyanine photosensitizer Pc 4 was obtained from
Dr. Malcolm Kenney (Case Western Reserve University) [97]. A stock solution of
0.5 mM was made in dimethyl formamide and diluted into complete culture medium.
Cells (360,000/dish) were cultured on 60-mm Petri dishes in complete culture mediurn for 24 h.

~ubsequently,

cells were incubated with Pc 4 concentrations, as indicat-

ed, for 18 h and then washed twice

w~.th

PBS and lysed in 0.5% sodium dodecyl sul-

fate (SOS). Cell lysates were collected and fluorescence was measured with a fluorometer (Photon Technology International, Birmingham, NJ) using 610 nm excitation and 630-720 nm emission.

A calibration curve was constructed by adding

known concentrations of Pc 4 to the lysates.

Subcellular Localization of Pc 4. Cells were cultured onto 35-mm glass-bottomed
Petri dishes (MatTek Corporation, Ashland, MA) at 150,000 cells/dish and incubated
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for 24 h. Subsequently, UMSCCl, UMSCC14A and UMACC22A cells were loaded
with Pc 4, as indicated, for 18 h. Medium was aspirated and changed to fresh mediurn supplemented with Insulin-Transferrin-Selenium-X (ITX) reagent [insulin (10
f.lg/ml) , transferrin (S.S Jlg/ml), selenium (6.7 ng/ml), ethanolamine (0.2 mg/ml)]
(Gibco), and omitting FBS

To assess co-localization of Pc 4 with mitochondria,

cells were loaded with SOO nM rhodamine 123 (RhI23) for 20 min. Medium was
changed with fresh medium containing 50 nM Rh123. Dishes were placed in an environmental chamber at 37°C on the stage of Zeiss LSM 510 laser scanning confocal
microscope (Zeiss, Germany). A 63 X N.A. 1.4 oil immersion planapochromat objective was used for all experiments. Rh123 and Pc 4 fluorescence was imaged using
488 nm excitationiSOO-S30 nm emission and 543 nm excitationlS60 nm long pass
emission, respectively.

Photodynamic Therapy. Cell cultures were incubated with the desired concentration of Pc 4 for 18 h before exposure to 390 mJ/cm 2 red light (A.

=

670 nm) at 37°C

from an Intense-HPD 7404 diode laser (North Brunswick, NJ). Subsequently after
exposure to red light, cells were incubated for various periods of time prior to analySIS.

Assessment of Cell Death. Cell death was assessed by propidium iodide (PI) using
a multi-well fluorescence plate reader, as previously described [207]. Briefly, cells
were cultured on 96-well plates (6,000 cells/well) for 24 h in complete culture medi-
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urn. Pc 4 in the presence or absence ofDFO (1 mM), sDFO (1 mM) and Ru360 (10
f.lM) were present during the last 18 h of the incubation, where indicated. Subsequently, medium was replaced with fresh medium supplemented with ITX reagent
and PI (30 f.lM) but without FBS. Bafilomycin (50 nM) was added as indicated.
One h after drug addition but before irradiation, PI fluorescence was measured using
530 nm excitation (25 run band pass) and 620 run emission (40 run band pass) filters.
PI fluorescence was then measured at frequent intervals for 8 h. Between measurements, microtiter plates were placed in a 37°C incubator. At the end of the experiment, digitonin (200 J.lM) was added to each well to permeabilize all cells and label
all nuclei with PI. Percentage viability (V) was calculated as V = lOO(B-X)/(B-A),
where A is initial fluorescence, B is fluorescence after addition of digitonin, and X is
fluorescence after any given time. Cell viability determined by PI fluorometry is essentially the same as cell viability determined by trypan blue exclusion [207].

Apoptosis was determined from nuclear morphology after PI staining in the
presence of digitonin. At indicated time points, floating and adherent cells were collected, centrifuged and resuspended in PBS containing 100 f.lM digitonin and 30 f.lM
PI. Digitonin permeabilizes the plasma membrane and allows PI to enter cells and
stain all nuclei. Thus, PI staining in the presence of digitonin is equivalent to staining with Hoechst and DAPI, the two fluorescent dyes most commonly used to assess
apoptosis by nuclear morphology. Apoptotic nuclei were scored as apoptotic based
on nuclear condensation and fragmentation and counted with a 40X microscope ob-
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jective using a rhodamine filter set and expressed as a percentage of total cells. At
least 200 cells were counted from three different microscopic fields for each sample.

Caspase 3/7 Activity. Caspase-3/7 activity was measured using a Caspase-GloTM
3/7 kit (Promega, Madison, WI) according to the manufacturer's instructions. At
indicated time points, cultured cells were scraped into a test tube followed by centrifugation. The pellet was resuspended and lysed with RIPA (150 mM NaCI, 1 mM
EGTA, 1% sodium deoxycholate, 1% Triton X-100, 50 mM Tris-CI, pH 7.4) buffer.
Caspase-Glo™ 3/7 reagent and the lysate were mixed in 1: 1 ratio, and luminescence
was measured with a luminometer. The resulting luminescence was proportional to
caspase activity.

Clonogenic Assay. Cells (330,OOO/dish) were cultured on 60-mm Petri dishes for 24
h. Subsequently, cells were loaded with 25 nM Pc 4 for 16-18 h. One hour prior to
irradiation, 50 nM bafilomycin was added, as indicated. Immediately after irradiation, cells were harvested by trypsinization. Aliquots of cell suspensions were plated
onto 60-mm Petri dishes in amounts sufficient to yield 50-100 colonies per dish. After 14 days in complete culture medium, colonies were stained with 0.1 % crystal violet in 20% ethanol and counted by eye.
Lysosomal Integrity. To assess the lysosomal integrity, cells were incubated with
0.2 mg/ml of Alexa-488 dextran (10 kDa) for 18 h. Alexa-488 dextran is taken up
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by cells via endocytosis. Alexa-488 fluorescence was imaged by confocal microscopy (488 nm excitationl500-530 run emission). Bright green dots co-localized with
lysosome-specific fluorophores (data not shown), such as LysoTracker Red, indicating that Alexa-488 dextran can be used as an endosomai/lysosomal marker. To assess LysoTracker Red release from lysosomes, cells were incubated with LysoTracker Red (500 nM) for 20 min at 37°C in complete culture medium. Medium was replaced with fresh medium supplemented with 200 nM LysoTracker. LysoTracker
Red fluorescence was imaged by confocal microscopy (543 run excitationl560 nm
long pass emission).

Statistical Analysis. Data are calculated as means ± SEM from at least three inde-

pendent experiments performed in triplicate. Pairwise comparison was performed by
two-tailed I-test using Instat2 software (GraphP AD, San Diego, CA). A p value <
0.05 was considered to be statistically significant.
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Results

Cellular Uptake and Subcellular Localization of Pc 4 in Head and Neck Cancer
Cells
Pc 4 is a hydrophobic photosensitizer that diffuses freely across the plasma
membrane and binds to membranes of intracellular organelles [204]. Three different
head and neck cancer cell lines were incubated with different concentrations of Pc 4,
as indicated in Fig. 2-1 A. Cellular Pc 4 uptake was determined by cell lysates. The
3 cell lines took up Pc 4 differently in the order ofUMSCC22A, UMSCC14A, UMSCC1 (Fig.2-1A). To achieve an equal cellular Pc 4 uptake among cell lines, UMSCC14A and UMSCC1 cells required higher loading concentrations of Pc 4 to yield
the same Pc 4 uptake as UMSCC22A cells (Fig. 2-1A). Subcellular localization of Pc
4 was determined at equal cellular Pc 4 content (1.5 pmol/mg) using confocal mi~

croscopy. To determine co-localization of pc 4 with mitochondria, cells were loaded
with rhodamine 123, a mitochondria-specific probe. In all three cell lines, overall Pc
4 pattern and co-localization of Pc 4 with rhodamine 123 was similar (Fig. 2-1B).

Head and Neck Cancer Cells Respond Differently to PDT
After determination of the Pc 4 loading concentrations that resulted in equal
cellular Pc 4 uptake between 3 different head and neck cancer cells, we determined
their individual sensitivity to Pc 4-PDT. Sensitivity to Pc 4-PDT was determined at
3 different levels of cellular Pc 4 content. All 3 cell lines were resistant to PDT at
the Pc 4 uptake of 0.8 pmol Pc 4/mg protein (Fig. 2-2A). At the Pc 4 uptake of 1.5
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pmol Pc 4/mg protein, Pc 4-PDT had minimal toxicity in UMSCC1 and UMSCC14A
cells (Fig. 2-2A). In contrast, UMSCC22A cells were more sensitive, and cell viability was decreased to 15% after 8 h (Fig. 2-2B). At even higher Pc 4-PDT dosages
(2.8 pmol Pc 4/mg protein), differences in sensitivity between cell lines were diminished (Fig. 2-2C). Thus, we identified the Pc 4-PDT resistant and responsive head
and neck cancer cells at 1.5 pmol Pc 4/mg protein. Since UMSCCI and UMSCC14A
cells behaved similarly regarding sensitivity to PDT, we decided to concentrate on
UMSCC 1 and UMSCC22A in further experiments. Results shown in (Fig 2-1 and
Fig 2-2) demonstrated that head and neck cancer cells responded differently to the Pc
4-PDT while the difference in sensitivity cannot be explained by equivalent cellular
uptake and similar patterns of Pc 4 subcellular localization.

Bafilomycin Enhances PDT Killing in Both Resistant and Responsive Cell Lines
It has been known that lysosomes can be an alternative target in cases of failed
mitochondrial targeting therapy. Therefore, our lab took the pharmacology approach
by combining the bafilomycin, an inhibitor of the vacuolar proton-pumping ATPase
(H+ -ATPase), which collapses lysosome pH and releases lysosomal iron to the mitochondria [205], with the mitochondria localized Pc 4-PDT. Results showed that
bafilomycin enhances mitochondria-mediated Pc 4-PDT killing in A431 cells as
shown in (Fig 2-3A) as well as results obtained from another lysosomal alkalinization agent, chloroquine which is a weak base and accumulates into lysosomal acidic
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vesicles to raise their pH. Chloroquine has the same biological effect as bafilomycin.
Neither chloroquine nor bafilomycin alone with PDT induced cell killing but, when
combined with Pc 4-PDT, both enhanced Pc 4-PDTcytotoxicity (Fig. 2-3A). In addition, the effects of bafilomycin on Pc 4-PDT treated A431 cancer cells were further
confirmed by clonogenic assay, which measures the effect of a reagent on cancer cell
survival and proliferation (Fig. 2-3B). Bafilomycin plus Pc 4-PDT treated A431 cells
showed decreased proliferation and survival compared to the Pc 4-PDT.

Cell death type by bafilomycin enhanced Pc 4-PDT killing was further determined by PI nuclear morphology staining and caspase activity assay. The PI fluorometry assay monitors failure of the plasma membrane permeability barrier, an
event that occurs during necrosis and lat1e stage apoptosis, the latter often named sec~

ondary necrosis. To determine further the mode of cell death, apoptosis and caspase
3/7 activity were monitored. Both caspase-3/7 activity and apoptotic death were enhanced by bafilomycin after Pc 4-PDT treatment. Moreover, the pan caspase inhibitor z-V AD completely blocked Pc 4 plus bafilomycin-induced caspase activation and
apoptosis (Fig. 2-4). Overall, the results indicate that bafilomycin enhances mitochondria targeted Pc 4-PDT cytotoxicity but alone is nontoxic.
We assessed the effect ofbafilomycin on PDT-induced cell killing in the UMSCCl and UMSCC22 head and neck cancer cell lines. At 0.8 pmol Pc 4/mg protein,
Pc 4-PDT alone or in combination with bafilomycin induced minimal toxicity in
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UMSCCI cells (Fig. 2-5A). Bafilomycin alone or light alone caused no toxicity (data not shown). At higher Pc 4 loading (1.5 pmol Pc 4/mg protein), its combination
with bafilomycin caused 100% cell death after 5 h exposure to Pc 4-PDT (Fig. 2-5A)
in UMSCC1 cells.

In UMSCC22A cells, 0.8 pmol Pc 4/mg protein caused no toxicity during PDT,
but its combination with bafilomycin greatly enhanced cell killing and decreased viability from 93% (Pc 4-PDT alone) to 17% (Pc 4-PDT plus bafilomycin) (Fig. 2-5B).
At even higher Pc 4 loading (1.5 pmol Pc 4/mg protein), Pc 4-PDT greatly induced
cell killing, and bafilomycin did not further enhance it since the UMSCC22 cells are
already very sensitive to the higher Pc 4 dose (1.5 pmol Pc 4/mg protein) alone.
When another lysosomal alkalinization ,reagent, chloroquine, was applied to further
I"'

observe the dysregulated pH effect of lysosome on Pc 4-PDT, we obtained similar
PDT-enhanced cytotoxicity results (data not shown).

These results suggest that, for those in whom mitochondrial targeted PDT therapy has shown failure or resistance, lysosomal alkalinization agents represent a feasible combination adjuvant to increase PDT treatment efficacy.
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Iron Chelators and Ru360 Protect Against Bafilomycin-Enhanced PDT Killing
Studies from hepatocytes demonstrate that bafilomycin releases iron from lysosomes to the cytosol [205]. Therefore, we characterized whether chelation of iron
would protect against bafilomycin-enhanced cell killing during PDT.

Cells were

pretreated with DFO (lmM) for 18 h before bafilomycin and subsequent irradiation.
In UMSCC 1 cells at 1.5 pmol Pc 4/mg protein, DFO increased cell viability from 0
to 37% after 5 h (Fig. 4A). starch-DFO (sDFO) (lmM), which is taken up by endocytosis and specifically chelates endosomai/lysosomal iron, protected against cell
killing after Pc 4-PDT to an even greater extent than DFO, increasing viability from

o to 52% after 5 h

(Fig. 2-6A). Ru360 is a highly specific inhibitor of the mitochon-

drial electrogenic calcium uniporter [205]. When cytosolic Fe 2+ increases, the calciurn uniporter transports iron into mitochondria [92].

Ru360 (10 J-lM) blocked

,
~

bafilomycin-enhanced PDT killing increasing viability from 0 to 79% after 5 h in
UMSCC 1 cells (Fig. 2-6A).

Similarly, in MUSCC22A cells, DFO and sDFO greatly protected against
bafilomycin-enhanced PDT (0.8 pmol Pc 4/mg protein) toxicity, increasing viability
from 17% to 690/0 and 60% in the presence ofDFO and sDFO, respectively, after 8 h
(Fig. 2-6B). Again, Ru360 provided even greater protection, with viability increasing from 17 to 87%. Cytoprotection by iron chelators indicates that bafilomycininduced toxicity during PDT is mediated by the release of lysosomal iron to the cyto-
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sol. Toxicity was likely related to increased mitochondrial iron uptake, since Ru360
greatly blocked toxicity.

Lysosomal Iron Augments Bafilomycin plus Pc 4-PDT-Mediated Cell Killing
Results from another group [205] and the iron chelators and calcium uniporter
inhibitor tested in these experiments both suggested that bafilomycin enhanced Pc 4PDT killing through lysosomal iron release and mitochondrial iron uptake, as shown
in Fig. 2-6 .To further assess whether iron participates in cell killing after Pc 4-PDT,
we pre-incubated A431 cells with 30 JlM ammonium iron (III) citrate (Fe 3+) for 24 h
before Pc 4 loading. Fe 3+ binds to transferrin, which is taken up by cells through receptor-mediated endocytosis, resulting in increased lysosomal iron. After Fe 3+ loading, cells were loaded with Pc 4 followoo by bafilomycin or vehicle and light irradiation. At the low concentration of Pc 4 used, PDT in the absence and presence ofFe 3+
caused virtuaily no toxicity (Fig. 2-7). However, in the presence ofbafilomycin, Fe 3+
nearly doubled the rate of bafilomycin Pc 4-PDT-induced killing, decreasing viability to 25% from 47% at 12 h after PDT. This result indicated that iron taken up into
the lysosome and released into the cytosol by bafilomycin contributes to the increased PDT killing effect.
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Bafilomycin Enhanced Pc4-PDT Killing through Lysosomal Iron Release without
Causing Lysosomal Membrane Permeability

To detennine whether bafilomycin-enhanced mitochondrial dysfunction after
POT was dependent on lysosomal membrane breakdown, cells were preloaded with
Fe3+, Alexa-488 dextran (10 kDa), and Pc 4 (25 nM). Alexa-488 dextran is taken up
by endocytosis to label endosomes/lysosomes as bright fluorescent dots (Fig. 2-8A,
Pc 4+Fe). Subsequent 1 h exposure of bafilomycin did not change endosomal
Ilysosomal integrity (Fig. 2-8A, +Baf). After 2 h of irradiation (Fig. 2-8A, +light),
when mitochondrial depolarization was maximal, there was no change in Alexa-488
dextran fluorescence (Fig. 2-8A, +Baf+Light), mitochondria depolarization image is
not shown). This result indicated that bafilomycin released lysosomal iron to cause
mitochondrial depolarization without breaking the lysosomal membrane; otherwise,
,.,

the small 10 kOa Alexa-488 dye would have leaked out and decreased the lysosomal
labeling intensity. On the other hand, to further confirm that bafilomycin collapsed
lysosomal pH gradient, cells were loaded with LysoTracker Red (500 nM) and subsequently exposed to bafilomycin. LysoTracker Red is a weak base and accumulates
into acidic organelles such as lysosomes [208]. Inhibition of the vacuolar protonpumping ATPase with bafilomycin is well established to collapse lysosomal pH gradients and induce lysosomal alkalinization where the LysoTracker Red can no longer
be retained in increased pH environment. Result from (Fig. 2-8B) showed that release of LysoTracker Red after bafilomycin in our experiments confinned that
bafilomycin does collapse the lysosomal pH in the treated cells as expected (Fig. 2-
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8B). At the same time, we also loaded lysosomes with Alexa-488 dextran (10 kDa)
in other dishes. After 1 h exposure to bafilomycin, lysosomes retained Alexa-488
dextran but released LysoTracker Red (compare Fig. 2-8 A with B).

Bright LysoTracker Red-labeled spots disappeared after bafilomycin administration, indicating lysosomal alkalinization (Fig. 2-8B). These results indicate that
bafilomycin-enhanced

mitochondrial

dysfunction

was

not

due

to

endoso-

mal/lysosomal membrane breakdown but rather was caused by collapse of the pH
gradient in these organelles, which promotes release of lysosomal chelatable iron
into the cytosol. Taken together, these findings suggest that lysosomal alkalinization
by bafilomycin released iron without causing the generalized lysosomal membrane
permeabilization. Additionally, imaging10f Alexa-488 dextran did not show evidence
~

of lysosomal swelling after bafilomycin, which would be expected as a colloid osmotic effect if the membrane became nonspecifically permeable to smaller molecular
weight solutes. Indeed, nonspecific permeabilization to small or large molecular
weight solutes has never been described for bafilomycin. Rather bafilomycin is a
very specific and high affinity inhibitor of the lysosomal proton pump [209].
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Ferristatin Protects Cells against Bafilomycin-Mediated PDT Toxicity

Although the mechanism by which bafilomycin releases iron from lysosomes
was unclear until these results, findings from our lab and others have clearly showed
that bafilomycin releases lysosomal iron without physically damaging the lysosomal
membrane [92, 205]. In normal physiology, cells store ferrous iron in endosomes/lysosomes and move iron out of lysosomes through the DMT1 [210]. This
phenomenon suggests a possible lysosomal iron releasing mechanism by bafilomycin
through the DMT1.

With the attempt to study the putative role of bafilomycin in releasing lysosomal
iron into the cytosol by DMT1, a pharmacologic approach was taken by applying
ferristatin, an inhibitor ofDMT1 [211] t9 bafilomycin-treated Pc 4-PDT. PDT results
from UMSCC22A cells showed that ferristatin markedly protected cells against
bafilomycin-etmanced PDT toxicity (Fig. 2-9) if pre-incubated more than 4 h prior to
,-

bafilomycin addition. Moreover, ferristatin failed to protect if it was added after
bafilomycin (not shown), which had therefore already released lysosomal iron. These
findings strongly support and suggest the possible mechanism of lysosomal iron release by bafilomycin via DMT1 (Fig. 2-9).
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Chloroquine Retards Regrowth of Tumors after PDT

Our in vitro data show that bafilomycin greatly enhances Pc 4-PDT efficacy in
Mfrn2-expressing cells. Thus, we hypothesized that adjuvant bafilomycin or chloroquine would enhance tumor response to Pc 4-PDT, especially in high Mfm2expressing tumors. Instead ofbafilomycin, we used chloroquine in this study. Chloroquine showed the same enhanced PDT killing effects as bafilomycin in cancer cell
lines (Fig. 2-3A). Chloroquine acts similarly to bafilomycin in collapsing the lysosomal pH gradient and releasing iron from the lysosomes [92]. Moreover, the advantage of chloroquine over bafilomycin for in vivo experiments is that chloroquine
is already approved for human use by the FDA and has a long safe use record in humans. Xenografts were created with UMSCC22A cells in nude mice and subjected
to Pc 4-PDT. Tumor size continued to increase progressively after exposure to light
without the photosensitizer (light only) or light plus chloroquine (CHQ) without the
photosensitizer. By contrast, with the photosensitizer, tumors disappeared within the
first 4 days post-PDT. Subsequently, tumors in the Pc 4 group started to regrow
(Pc4). Chloroquine, however, significantly (p=0.011) delayed tumor regrowth
(Pc4+CHQ) as plotted in Kaplan-Meier form (Fig. 2-10). These pilot data provide
proof of principle that chloroquine can enhance the efficacy of PDT in vivo.
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Discussion

Mitochondrial apoptotic cell death is considered an efficient approach for cancer therapy. However, cancer cells constantly develop mutations within molecules
that participate in the apoptotic cell death pathway, resulting in ineffective cancer
treatment [212]. Accumulating literature reports that lysosomes can be alternative
cellular targeting organelles to enhance therapy [213, 214]. Using a pharmacologic
approach, we determined how lysosomes contribute to PDT-induced by mitochondria-targeted photo sensitizers , such as Pc 4. Our results show that bafilomycin greatly accelerates mitochondria-specific Pc 4-PDT-mediated cell killing.

Although

bafilomycin acts on lysosomes, its toxic effects were manifested in mitochondria by
accelerated depolarization after PDT, resulting in caspase 3/7 activation and apoptotic death. The findings indicate cross talk between lysosomes and mitochondria during PDT.
The endosomai/lysosomal compartment continuously receives iron by transferrin receptor-mediated endocytosis and by autophagic digestion of iron-containing
proteins [180, 194]. Thus, lysosomes are a reservoir of chelatable, redox-active Fe 2+.
Fe2+ reacts with H 2 0 2 to generate highly reactive and toxic OH

e
•

During Pc 4-PDT, a

large proportion of ROS formation occurs inside mitochondria and leads to the onset
of a mitochondrial permeability transition, as documented by increased mitochondrial dichlorofluorescein fluorescence and the movement of calcein across the mitochondrial inner membrane [204].
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The alkalinization of lysosomes/endosomes with bafilomycin enhanced Pc 4PDT-mediated cell killing (Fig. 2-3 and Fig. 2-5). However, bafilomycin did not induce lysosomal membrane breakdown after Pc 4-PDT, as assessed by retention of 10
kDa Alexa-488 dextran with lysosomes (Fig. 2-8A). Alexa-488 dextran fluorescence
is pH-independent, and, therefore, the loss of Alexa-488 dextran fluorescence signifies lysosomal disintegration specifically rather than indicating a change in lysosomal pH. These results indicate that lysosomal membranes remained intact during
bafilomycin plus PDT treatment (Fig. 2-8A). Since lysosomal membrane permeabilization did not occur, the possibility of cathepsins and other proteases to be released
from lysosomes and contribute to PDT cytotoxicity was ruled out.
Fe3+ forms a complex with transferrin, which binds to transferrin receptors for
receptor-mediated endocytosis, resulting in iron delivery to endosomes/lysosomes.
,.,

The observation that pre-incubation of cells with ammonium iron (III) citrate en.,

hanced killing after bafilomycin plus Pc 4-PDT treatment and that sDFO prevented
this cell killing is consistent with the conclusion that bafilomycin mobilizes iron
from lysosomes into the cytosol. Similar results were obtained in a recent study with
He La cells, where FeCl3 enhanced ionizing radiation-induced killing that was prevented by iron chelation [215].
Our results established that lysosomal iron release mediates bafilomycinmediated enhanced killing during PDT. However, the mechanism by which bafilomycin releases iron from lysosomes remains unclear. The release of iron occurred
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without physical damage to lysosomal membranes (Fig. 2-8A). In normal cell physiology, Fe2 + stored in endosomes/lysosomes moves out of lysosomes through the
DMTI [211]. Therefore, we assessed the possibility of lysosomal iron to be released
by bafilomycin through DMTI. Ferristatin, an inhibitor ofDMTl [216,217] markedly protected against bafilomycin-enhanced toxicity (Fig. 2-9). Ferristatin failed to
protect if it was added after bafilomycin (not shown) and thus after lysosomal iron
release. These results support the conclusion that iron release after bafilomycin occurs via DMTI. Evidently these results need to be confirmed using a knockdownlknockout approach.

Fe2 + reacts with R 2 0 2 to fonn ORe, a highly reactive fonn of ROS [194].
Bafilomycin by itself was not sufficient, to induce cell killing (data not shown). Ra10

ther, mild oxidative stress induced by low dose Pc 4-PDT combined with bafilomy.,

cin was needed to induce cell killing (Fig. 2-3). The iron chelators DFO and sDFO
protected against PDT plus bafilomycin-induced mitochondrial depolarization and
killing (Fig. 2-6, and Fig. 3-4A) [92]. DFO is highly polar and poorly permeates
through membranes, and therefore millimolar concentrations were required to have
the protection effect. DFO may also be taken up by endocytosis resulting in its accumulation in endosomes/lysosomes [180]. Consequently, cytoprotection with DFO
may be explained by chelation of redox-active iron in lysosomes. sDFO also prevented PDT plus bafilomycin-induced cell killing (Fig. 2-6), indicating that lyso-

69

somes/endosomes release redox-active iron after bafilomycin and that DFO and
sDFO prevent this release by chelating the intraluminal iron store of these organelles.
Protection by lysosomal iron chelation against mitochondrial depolarization
[92] after PDT suggests that mitochondrial iron uptake may be responsible for
bafilomycin-enhanced killing. Mitochondria accumulate Fe2+, but not Fe3+, electrogenically via the MCV [218,219]. The highly specific inhibitor of MCU, Ru360,
also protected against bafilomycin-enhanced PDT toxicity (Fig. 2-6).

Although

Ru360 and iron chelators blocked cell killing, Ru360 was somewhat more effective
in protecting against cell killing (Fig. 2-6). Thus, mitochondrial iron uptake seems to
be a key event in bafilomycin-enhanced PDT toxicity.
Besides chelating iron, DFO also stabilizes HIF-la in normoxic cells [220].
HIF-la activates several protective signaling
pathways that potentially could explain
,
,.

cytoprotection by iron chelation. Although DFO and sDFO did stabilize HIF-1a protein levels, R1l360 did not (Fig. 2-11) [92]. Since Ru360 protected against cell killing even better than DFO/sDFO

(Fig.~

2-6) [92], HIF-la is not likely responsible for

cytoprotection.
Bafilomycin is frequently used to inhibit autophagy by collapsing lysosomal
pH gradients and thereby blocking fusion of autophagosomes with lysosomes [221].
Consistently with an effect on autophagy, bafilomycin alone and Pc 4-PDT plus
bafilomycin increased cellular LC-3 II protein levels as assessed by Western blotting,
presumably by inhibiting fusion of autophagosomes with lysosomes (Fig. 2-12).
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Thus, bafilomycin inhibited autophagic flux, which may explain the increased PDT
killing with bafilomycin. However, iron chelators and Ru360 protected cells against
Pc 4-PDT plus bafilomycin toxicity, but neither iron chelators nor Ru360 altered LC3 II protein levels (Fig. 2-12). Thus, it seems unlikely that enhanced survival by iron
chelators and Ru360 acts through enhancing autophagy. Rather, iron chelators and
Ru360 prevented cell killing induced by bafilomycin during PDT (Fig. 2-6).
In conclusion, we established a link between lysosomal alkalinization and mitochondrial depolarization during PDT (Fig. 2-13) [92]. Strategies to engage lysosomes in cell death pathways have potential to enhance tumor cell killing. Our results here demonstrate that strategies to collapse the lysosomal pH gradient without
lysosomal membrane breakdown are sufficient to induce iron-dependent cell killing.
Lysosomal perturbation by bafilomycin effectively enhances cell killing during PDT.

.
,

Pc 4-PDT has completed a Phase I clinical trial for cutaneous neoplasms [98] and is
currently in a Phase I trial for psoriasis. The results of this study suggest that agents
that disturb lysosomal function could potentially be used clinically as an adjuvant
treatment with mitochondria-targeted photosensitizers.
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Figure 2-1. Cellular uptake and sub-cellular localization of Pc 4 in head
and neck cancer cells. UMSCC1, UMSCC14 and UMSCC22A cells have (A)
equivalent cellular Pc 4 uptake under the loading of Pc 4 at concentration of 75300, 100-375, and 125-451 nM, respectively. Values were normalized to protein
content and results represent three independent experiments (mean ± SEM). (B)
Similar Pc 4 cellular localization patterns. Images are representative of three
independent experiments.
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Figure 2-2. Head and neck cancer cells respond differently to PDT. UMSCC1 and UMSCC 22A cells respond to PDT dose at (A) 0.8 (B) 1.5 and (C)
2.8 pmol Pc 4/mg protein, as described in Fig. 2-1A. After 18 h, medium was
changed to fresh medium supplemented with ITX reagent and PI (30 JlM) but
omitting FBS. Cells were exposed to light as described in Materials and
Methods. Viability was assessed by PI exclusion using fluorometry. Results
are expressed as percent viability at 0 h. Data represent three independent
experiments (mean ± SEM) performed in quadruplicate. *, p < 0.0001 compared to UMSCC 1 and UMSCC 22A.
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Figure 2-3. Chloroquine enhances Pc 4-PDT-induced A431 cell killing. (A)
Both bafilomycin and chloroquine enhance Pc 4-PDT cytotoxicity. 50 nM bafilomycin or 50 flM chloroquine was added 1 h before irradiation, and cell viability
was monitored with PI fluorometry. Results are expressed as percent viability of 0
h. Data represent three independent experiments performed in quadruplicate. (B)
Cells (330,000 cells/6-cm Petri dish) were treated and irradiated as in A. Subsequently, cells were trypsinized and plated on 6-cm Petri dishes. After 14 days,
colonies were stained with crystal violet and counted. Results are expressed as
percent colonies of light-treated cultures. Data represent three or more independent experiments performed in triplicate. *, p < 0.05 compared to Pc 4 (one-tailed
t-test).
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Figure 2-4. Bafilomycin enhances Pc 4-PDT killing in A431 cancer cells
through apoptotic death. (A) cells ,., were plated on 96-well plates (6,000
cells/well) and treated as described in exp€rimental procedures. z-VAD (10 J..lM)
was added, as indicated, 1 h prior to irradiation. Four h after irradiation, apoptotic
nuclei were scored with a fluorescence microscope as described in materials and
methods. At least 200 cells were counted from three different microscopic fields
for each treatment group. Results are expressed as percent apoptotic nuclei. Data
represent three independent experiments (mean ± SEM) performed in triplicate.
***, p < 0.005 compared to Pc 4. (B) cells were plated on 6-well plates (120,000
cells/well) and treated as described in A. Four h after irradiation, celllysates were
prepared as described in Materials and Methods. Caspase 3/7 activity was normalized for protein content, and results are expressed as fold increase from lighttreated cells. Data represent three independent experiments (mean ± SEM) performed in triplicate. *, p < 0.05 compared to Pc 4 (one-tailed t-test).
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Figure 2-5. Bafilomycin enhances PDT killing in both resistant and responsive
cell lines. UMSCC1 (A) and UMSCC22A (B) cells (6,000 cells) were cultured on
96-well plates for 24 h. Cells were incubated with Pc 4 to yield to 0.8 and 1.5
pmol/Pc 4/mg protein, as described in Fig. 2-1 A. After 18 h, medium was changed
to fresh medium supplemented with ITX reagent and PI (30 JlM) but omitting
FBS, followed by incubation with bafilomycin (50 nM) (Bat) for 1 h, where indicated. Subsequently, cells were exposed to light, as described in Materials and
Methods. Viability was assessed by PI exclusion. Data represent three independent experiments (mean ± SEM) performed in quadruplicate. *, p < 0.0001 compared to Pc 4-PDT treatment alone.
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Figure 2-6. Iron chelators and Ru360 protect against bafilomycin-enhanced
PDT killing. UMSCCI (A) and UMSCC22A (B) cells were loaded with Pc 4 in
the presence and absence of iron chelators DFO (1 mM) and sDFO (1 mM), and
the inhibitor of the calcium uniporter Ru360 (10 J.!M) for 18 h. Cells were irradiated and cell killing was assessed with PI exclusion, as described in materials and
methods. Values are mean ± SEM from 3 independent experiments. *, p < 0.05
compared to Pc 4+Baf.
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Figure 2-7. Iron enhances Pc 4-PDT-induced A431 cell killing. Cells were
cultured in medium containing 30 f.lM ammonium iron (III) citrate (Fe) for 24 h,
as indicated. Subsequently, Fe3+ was washed out and cells were incubated with
25 nM Pc 4 for 18 h. Medium was replaced with medium supplemented with
Insulin-Transferrin-Selenium-X Reagent and omitting FBS. Bafilomycin (50
nM) was added, as indicated. Cell viability was monitored with PI fluorometry.
Data represent three independent experiments (mean ± SEM) performed in quadruplicate. *, p < 0.05; **, p < 0.01 compared to Pc 4 + Baf.
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Figure 2-8. Lysosomal membrane permeability after bafilomycin and Pc 4PDT in A431 cells. (A) cells were plated on glass-bottomed Petri dishes (150,000
cells/dish) in the presence of Fe. After 24 h, medium was replaced with fresh medium containing 25 nM Pc 4 and Alexa-488 dextran (10 kDa, 0.2 mg/ml). After 18 h,
medium was replaced with fresh medium supplemented with ITX reagent and omitting FBS. Dishes were placed on a confocal microscope stage at 37°C. Images were
obtained after Pc 4 and Fe (Pc 4+Fe), after 1 h exposure to bafilomycin (+Baf) and
after 2 h exposure to light (+Baf+Light). (B) cells were loaded with LysoTracker
Red (500 nM) for 20 min. Medium was replaced with fresh medium supplemented
with 200 nM LysoTracker Red. After collecting a baseline image, bafilomycin (50
nM) was added and the images were taken after 60 min (upper panel). Lower panel
shows untreated cells imaged before and after 60 min. Images in A and B are representative of three independent experiments.
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Figure 2-9. Ferristatin protects UMSCC22A cells against bafilomycin
enhanced Pc 4-PDT cytotoxicity. UMSCC22A cells were plated on 96 well
(15,0001 well) plate for 24 h. Subsequently, cells were loaded with 0.8 pmole
Pc 4/mg for 18h in complete DMEM medium with the ferristatin 4 h or 18 h.
Medium were then replaced with ITX medium with bafilomycin (50 nM) for
1 h prior to light exposure. Viability was assessed by PI exclusion.
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Figure 2-10. Effect of CHQ on tumor regrowth after Pc 4-PDT. UMSCC22A
cell xenografts were created in flanks of nude mice (3 xl 06 cells in right flank).
Once tumors reached 60-100 mm3, Pc 4 (0.5 mg/kg) was administered via tail vein.
After 48 h, CHQ (30 mg/kg, i.p.) was administered, as indicated. Four h later, tumors were irradiated (50 J/cm2). Post-PDT, tumor volume was measured with a digital caliper. The estimated difference and 95% confidence interval for Pc 4+CHQ
vs. Pc 4 was statistically significant (p = 0.011).
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Figure 2-11. Effect of iron chelators and Ru360 on HIF-la protein levels.
A431 cells were incubated with Pc 4 (25 nM) in the presence and absence of
DFO (1 mM), sDFO (ImM) and Ru360 (10 JlM) for 18 h, and celllysates
were subjected to Western blotting. Cells were also exposed to hypoxia
(0.5% O2) for 6 h as a positive control. Actin was used as a loading control.
Blots are representative of three independent lysates.
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Figure 2-12. Effect of DFO and Ru360 on autophagy during bafilomycin
plus Pc 4-PDT. UMSCC22A cell~ were plated on 6-well (300,000/well)
plates for 24 h. Subsequently, cells were loaded with 0.8 pmole Pc 4/mg in
the presence ofDFO (1 mM) and Ru360 (10 f.lM) for 18 h in complete medium. Medium was then replaced with ITX medium supplemented with
bafilomycin (50 nM) in the presence and absence of DFO or Ru360 for 1 h
prior to light exposure. Cell lysafes were prepared after 45 min post-PDT
treatment and probed with LC3 antibody.
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Figure 2-13. Proposed model for interplay between Iysosomes and mitochondria during PDT.
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Chapter 3

Role of Mitochondrial Iron Transporter Mitoferrin2 in
Pc 4-PDT Treatment
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Hypothesis
HNSCC cells expressing higher levels of Mfm2 are more sensitive to PDT and particularly to bafilomycin-enhanced killing during PDT.

Introduction
In physiological conditions, cytosolic free iron concentration is low. However,
in pathological conditions chelatable iron released from lysosomes can dramatically
increase cytosolic iron concentration [194, 205]. Free iron is rapidly taken up by mitochondria through the MCV [205,218,219,222]. MCV was recently characterized
as a 40 kDa mitochondrial membrane protein with channel activity [218, 219]. Besides Ca2 +, MCV can also transport Fe 2+ into mitochondria in a situation where cytosolie Fe2 + is elevated [222].

,.
I

In addition, another mitochondrial protein, Mfrn has been recently described as
an iron transporter across the inner mitochondrial membrane [223-225]. Mfrn2 protein has two functional analogues: Mfm 1 (Mfml) and Mfm 2 (Mfm2).

Mfml

(SLC25A37) is a 38 kDa protein that is highly expressed in erythroid cells and in
low levels in other tissues, whereas Mfm2 (SLC25A28), a 39 kDa protein, is expressed in non-erythroid tissue [199, 226-228]. Mfm transports iron into mitochondria to supply iron required for biosynthesis of heme and iron-sulfur clusters [229].
During erythropoiesis, half-life of Mfrn 1 increases in developing erythroid cells
whereas half-life of Mfrn2 remains the same [227]. Mfml deficiency in developing
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zebrafish erythroid cells results in deficient iron delivery and defective heme synthesis that cannot be rescued by ectopic expression of Mfm2 owing to different cellular
regulation of these two Mfm proteins [223]. Mfrn1 is also stabilized by Abcb10, a
mitochondrial inner membrane ATP-binding cassette transporter.

Abcb 10 and

Mfm1 form a complex, which further interacts with ferrochelatase to form an oligomeric complex that enhances mitochondrial iron importation during erythropoiesis
[230]. To date, no molecules have been identified to form a complex or interact with
Mfrn2.
Mfm2 belongs to family of the mitochondrial carrier family (MCF) and transports iron from cytosol into mitochondria. Mfm2 locates on the chromosome 10q 24
and contains four exons which encode a full length 364-aa protein with six transmembrane domains. Splice variant isoform2 and its four amino substituent isoform3
,.,

(NPAE

~

MALL) encode a 177-aa and. 176-aa proteins, respectively, with three

transmembrane domains [200]. Mfm2 full length isoform and the truncated isoform
2 are able to transport to mitochondria [199]. However, all the functional studies
with respect to iron transport into mitochondria are performed with full length Mfm2
and therefore the full length Mfrn2 is the canonical isoform. Mfm2 is expressed in
placenta, lung, kidney, pancreas, liver, brain, skeletal muscle and heart tissues [200].
In chapter 2, we demonstrated that bafilomycin releases iron from lysosomes
to cytosol and enhances Pc 4-PDT-mediated cytotoxicity in both the head and neck
responsive and resistant cell lines. In this study, we explored the potential contribu-
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tion of Mfm2 to PDT-mediated mitochondrial dysfunction and cytotoxicity after releasing lysosomal iron by bafilomycin. The findings implicate that lysosomal iron
release and mitochondrial iron uptake through Mfrn2 act synergistically to induce
PDT-mediated and iron-dependent mitochondrial dysfunction and subsequent cell
killing. To our knowledge, this is the first study to show a causal link between Mfm2
and mitochondrial dysfunction in a pathological condition.

,.,
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Materials and Methods

Cell Culture. The human head and neck squamous carcinoma cell lines (UMSCC 1,
UMSCC14A and UMSCC22A) were a gift from Dr. Besim Ogretmen (Medical University of South Carolina). Cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) (Gibco) supplemented with 10% fetal bovine serum (FBS) and penicillin/streptomycin (complete culture medium) in a humidified 37°C incubator at 5%
C02/95% air.

Photodynamic Therapy. Cell cultures were incubated with the desired concentration of Pc 4 for 18 h before exposure to 390 mJ/cm 2 red light (A

=

670 nm) at 37°C

from an Intense-HPD 7404 diode laser (North Brunswick, NJ). Subsequently after
exposure to red light, cells were incubated for various periods of time prior to analySIS

Assessment of Cell Death. Cell death was assessed by propidium iodide (PI) using
a multi-well fluorescence plate reader, as previously described [207]. Briefly, cells
were cultured on 96-well plates (6,000 cells/well) for 24 h in complete culture medium. Pc 4 in the presence or absence ofDFO (1 mM), sDFO (1 mM) and Ru360 (10
J.!M) were present during the last 18 h of the incubation, where indicated. Subsequently, medium was replaced with fresh medium supplemented with ITX reagent
and PI (30 J.lM) but without FBS. Bafilomycin (50 nM) was added as indicated.
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One h after drug addition but before irradiation, PI fluorescence was measured using
530 nm excitation (25 nm band pass) and 620 nm emission (40 nm band pass) filters.
PI fluorescence was then measured at frequent intervals for 8 h. Between measurements, microtiter plates were placed in a 37°C incubator. At the end of the experiment, digitonin (200 J.lM) was added to each well to permeabilize all cells and label
all nuclei with PI. Cell viability determined by PI fluorometry is essentially the same
as cell viability determined by trypan blue exclusion [207].

RNAi Knockdown. UMSCC22A cells (3 x 106 ) were transfected with human Mfm2
and non-target siRNA (25 nM, Ambion) using Lipofectamine RNAiMAX transfection reagent (Invitrogen) with a reversed transfection method on 10-cm Petri dishes.
After 3 days, cells were trypsinized and plated on 24-well plates (50,000 cells) for
the second reversed siRNA transfection:. After 3 days, cells were loaded with Pc 4 in
complete culture medium for 18 h for the experiments.

Quantitative Real Time peR. Total mRNA was extracted from celllysates using a
RNeasy Mini Kit (Qiagen) following the manufacturer's instructions. Quantitative
real time PCR (RT PCR) was performed by a two-step procedure. cDNA was synthesized by a iScript cDNA Synthesis kit (Bio-Rad) and PCR was carried out using
iQSYBR Green Supermix (Bio-Rad). Each PCR reaction contained 1 J.lI of the total
100 J.lI cDNA product from IJ.lg of total mRNA through RT process with 250 nM of
both forward and reverse primer. The PCR reaction was performed using the follow-
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ing protocol: 1 cycle of 3 min at 95°C for initial activation of the enzyme followed
by 40 cycles of lOs at 95°C for denaturation, and 45 s at 55°C for annealing and extension. After completion of the reaction, the PCR products were subjected to a melting curve analysis with 1 cycle of 1 min at 95°C to help denature and 1 min of 55°C
followed by 80 cycles of 55°C. Relative Mfm gene expression was quantified by
rI8S as a reference gene expression control. Primers for Mfm1 and Mfm2 were
adopted from Harvard Gene Bank as follows: Mfm1 (ID: 7706I50a1)-fw, 5'TAGCCAACGGGATAGCTGG-3' ;

Mfm1-rv,

5'GTGGTGTAGCTCCGGTAGAAG-3' (178 base pairs). Mfm2 (ID: 28703800aI)fW,5'CTGCGTGATGT ACCCCATCG3',
5'CCTGTTGCTGTGACGTTCAG-3 '

Mfm2-rv,
(1 59base

pairs).

18S-fw,

5' -

GAGGGAGCCTGAGAAACGG-3'; I8S-rv, 5'-GTCGGGAGTGGGTAATTTGC3' (68 base pairs).

Western Blot Analysis. Total cell extracts were prepared in ice-cold RIPA lysis

buffer [150 mM NaCI, 1 mM EGTA'~ 1% sodium deoxycholate, 1% Triton X-100,
0.1 % SDS, 1% NP40, 50 mM Tris-CI, pH 7.4] supplemented with a cocktail of protease inhibitors (Roche Diagnostics). Lysates were centrifuged, and resulting supernatants were quantified for the total protein content by Bradford (Bio-Rad). Equivalent amounts of protein were diluted in sample buffer (Invitrogen) supplemented
with 10% SDS and 10% J3-mercaptoethanol, and resolved on NuP AGE® Tris-bis
polyacrylamide gel (4%-12% SDS-PAGE) (Invitrogen). Proteins were transferred
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and immobilized on PVDF membranes (Millipore) and probed with anti-Mfm2
(1 :500) (Abeam), anti-TOM20 (1: 1000) (Santa Cruz), and

anti-~-tubulin

(1: 1000)

(Sigma). Membranes were developed by the enhanced chemiluminescence detection
system (Pierce).

Band intensities of the membranes were quantified using a

Caresteam 4000 PRO image station (Woodbridge, CT).

Mitochondrial Iron Uptake. Cells plated in 24-well plates were washed 3 times
with intracellular buffer (ICB) containing (in mM): 120 KCI, 10 NaCI, 2 MgCI 2 , 2.5
KH2P0 4, 20 HEPES buffer, pH 7.4,0.02 EGTA, 5 Na2 succinate, 2 ATP, 3 glutathione, 1 flM rotenone, 2 flM thapsigargin , 5 J.lM oligomycin, and 1 flg/ml protease inhibitors pepstatin, anti pain, and leupeptin leaving last wash. Ten J.lM digitonin was
added to last wash. After 10 min, buffer was substitute with ICB containing 5 J.lM
calcein, but no EGTA or digitonin and;'incubated for 5 min. Calcein fluorescence
(excitation 495 run emission 515'nm) was assayed every 0.5 sec for 120 sec using a
BMG Novostar fluorescence plate reader. After 1 sec,S J.lM FeS04 was added.

Statistical Analysis. Data are calculated as means ± SEM from at least three independent experiments performed in triplicate. Pairwise comparison was performed by
two-tailed (-test using Instat2 software (GraphP AD, San Diego, CA). A p value <
0.05 was considered to be statistically significant.
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Results

Differential Endogenous Mfrn-2 Gene and Protein Expression in Head and Neck
Cancer Cells
In non-erythroid cells, Mfm2 is an iron transporter localized on inner mitochondrial membrane that transports iron from cytosol into mitochondria [229]. Since
bafilomycin-induced toxicity during PDT is likely related to mitochondrial iron uptake, we assessed Mfrn2 expression in head and neck cancer cells. PDT-sensitive
cells (UMSCC22A) expressed 2 fold higher Mfrn2 mRNA measured by quantitative
peR compared to PDT-resistant (UMSCCI and UMSCC14A) cells. As expected,

all head and neck cancer cells expressed very little Mfml (Fig. 3-IA). Conversely,
human K562 erythromyeloblastoid leukemia cells expressed high levels of Mfml
and less Mfm2 (Fig. 3-IA). UMSCC22A expressed 2 fold higher Mfm2 protein lev,.,

els compared to UMSCCI and UMSCCI4A, and K562 cells expressed low Mfm2
(Fig.3-IB-C). Samples from all cell lines contained equal amounts of the mitochondria-specific protein TOM20 (Fig. 3-IC). Thus, the difference in Mfrn2 protein expression between the cell lines cannot be explained by differences in mitochondrial
proteins in lysates.

Next we determined whether cells expressing more Mfm2 were capable of
transporting iron faster from the cytosol to mitochondria compared to cells with less
Mfrn2. Mitochondrial iron uptake was measured in digitonin-permeabilized cells
using calcein fluorescence. Indeed, UMSCC22A cells showed higher rates of mito-
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chondrial Fe 2+ uptake compared to UMSCC1 cells (0.27 versus 0.08 J.1mol
Fe2+/minlmg protein) (Fig. 3-2).

Downregulation of Mfrn2 Results in Decreased Mitochondrial Fe 2 + Uptake
The results in Fig. 3-2 demonstrate the causal correlation of Mfm2 expression and mitochondrial Fe 2+ uptake in head and neck cancer cells. Therefore, we
reasoned that downregulation of Mfm2 in UMSCC22A cells should result in decreased mitochondrial Fe 2+ uptake. Knockdown of Mfrn2 in UMSCC22A cells using siRNA resulted in 88% decrease in Mfrn2 mRNA expression (Fig. 3-3 A) and
56% decrease in protein expression (Fig. 3-3B). As expected, knockdown of Mfrn2
also decreased rates of mitochondrial Fe 2 + uptake by 790/0 compared to cells transfected with non-target siRNA (0.31 J.1mol/minlmg versus 0.07 flmol/minlmg protein)
(Fig. 3-3C).

Taken together, the data are consistent with the conclusion that in-

creased mitochondrial iron transport through Mfrn2 at least partly explains the differential sensitivity of head and neck 'cancer cell lines to bafilomycin-enhanced toxicity to PDT. Furthermore, Mfm2 is likely a protein responsible for mitochondrial
iron transport in cells.
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Downregulation of Mfrn2 Delays Mitochondrial Depolarization and Cell Death
after PDT plus Bafilomycin

Iron by participating in Fenton chemistry and increasing ROS production can
induce mitochondrial dysfunction.

Therefore, we assessed the effects of Mfm2

knockdown on mitochondrial membrane potential and cell viability in high Mfm2
expressing UMSCC22A cells. At 0 min, bright pseudocolored red and yellow spheroids represented high TMRM fluorescence intensities in polarized mitochondria
(Fig. 3-4 A). After exposure to PDT (0.8 pmol Pc 4/mg protein) plus bafilomycin,
bright spheroids rapidly disappeared in cells transfected with non-target siRNA
(siControl) so that after 15 min, most ofTMRM had leaked out from mitochondria,
indicating mitochondrial depolarization. After 30 min, virtually all polarized mitochondria disappeared (Fig. 3-4 A top panel). Conversely, in Mfrn2 knockdown cells,
some of the bright fluorescent spheroids remained even after 30 min (Fig. 3-4 A bottom panel). The average TMRM fluorescence after background subtraction under
conditions described in panel A was

~etermined

every 5 min for 30 min. Results are

expressed as percent TMRM fluorescence of 0 min (Fig. 3-4 B). Data are means
calculated from analyses of 74-80 cells per treatment group obtained from three independent experiments (mean ± SEM).

*, P < 0.05 compared to control siRNA.

Moreover, Mfrn2 knockdown increased cell viability from 0 to 56% after 8 h (Fig. 34 C). The results implicate Mfrn2-mediated mitochondrial iron uptake as a key step
in bafilomycin-enhanced mitochondrial depolarization and subsequent cell death after PDT.
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Increased Expression of Mfrn2 Enhances Cell Death in Resistant Head and Neck
Cancer Cells after PDT Plus Bafilomycin

To further confirm the role of Mfrn2 in PDT response, we overexpressed the
Mfrn2 in low Mfrn2 expressing UMSCC 1 cells.

First Mfrn2-GFP-overexpressed

UMSCCI cells were loaded with MitoTracker Red to observe the cellular localization of the ectopic expressed protein. Confocal images revealed co-localization of
GFP and MitoTracker Red, indicating that GFP-Mfrn2 localizes to mitochondria (Fig.
3-5A). Next GFP-Mfrn2 protein levels were observed with both GFP and Mfm2 antibodies by Western blotting. We detected GFP-Mfm2 protein with both antibodies
(Fig. 3-5B). Next we assessed the effect of GFP-Mfrn2 on cell killing during PDT.
In GFP and GFP-Mfrn2 expressing UMSCCI cells, Pc 4-PDT alone decreased viability to 75% 8 h post-PDT (Fig. 3-6). In GFP expressing cells, bafilomycin enhanced Pc 4-PDT -induced cell killing decreasing viability from 75% to 45% at 6 h
post-PDT. In GFP-Mfrn2 expressing cells, however, viability decreased from 75%
to 0%. These results further confinn our results with knockdown cells and implicate
Mfrn2-mediated mitochondrial iron uptake as a key step in bafilomycin-enhanced
cell death after PDT.
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Discussion
Main findings of this study provide mechanistic information regarding the contribution of lysosomal chelatable iron to mitochondrial dysfunction and cell death in
HNSCC cells during PDT. Our results indicate that lysosomal iron release and mitochondrial iron uptake through Mfrn2 act synergistically to induce PDT -mediated and
iron-dependent mitochondrial dysfunction and subsequent cell killing in head and
neck cancer cells. To our knowledge, this is the first study to show a causal link between Mfm2 and mitochondrial dysfunction in a pathological condition.
Our results demonstrate that Ru360, a potent inhibitor of the MCU, markedly
protected against bafilomycin-mediated PDT toxicity (Fig. 2-6). For years, Ca2+ uptake across the inner mitochondrial membrane has been known to be mediated by the
Meu. However, it was until recently wren MeU was identified as a 40 kDa protein
~

that is localized to inner mitochondrial membrane. The protein contains two transmembrane domains and shows channel activity [218, 219]. However, transport of
Fe2+ into mitochondria through MeU occurs in pathological situation when cytosolic
free Fe2 +, but not Fe 3+, is increased [222].

Therefore, Ru360 protection against

bafilomycin toxicity during PDT may be explained by prevention of Fe 2+ uptake into
mitochondria through Meu.
Although MeU may serve as an iron transporter across mitochondrial membranes during pathological conditions, other iron transporters have been identified as
well. Mfm 1 is highly expressed in erythroid cells but in low levels in other tissues
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[223]. In non-erythroid cells, Mfrn2 is expressed as three isoforms, a canonical fulllength 39 kDa isoform and 2 alternative splicing isoforms [200]. So far only a fulllength Mfrn2 has been shown to transport iron from the cytosol to mitochondria
[199]. Thus, contributions of the other isoforms to the mitochondrial iron import remain to be determined. There is no sequence homology between MCU and Mfrn2
[218,219]. All three head and neck cancer cell lines expressed very little Mfrn1 (Fig.
3-1A). Interestingly, the cell lines that were more resistant (UMSCC1 and UMSCC14A) to PDT and bafilomycin toxicity also expressed less Mfrn2 mRNA and
protein than UMSCC22A, a sensitive cell line (Fig. 3-1A-B). Furthermore, mitochondria in permeabilized UMSCC22A cells took up Fe 2+ at a 3.0 fold faster rate
compared to UMSCC1 cells (Fig. 3-2). These findings suggest a causal link between
mitochondrial Fe 2+ uptake through Mfm2 and cytotoxicity.
,

Downregulation of Mfrn2 decrea;ed. rate of mitochondrial Fe 2+ uptake and delayed mitochondrial depolarization and subsequent cell death after PDT plus bafilomycin (Fig. 3-4A). Our results provide the first evidence how Mfm2 by regulating
mitochondrial Fe2+ uptake may contribute to cytotoxicity during PDT. The finding
that Ru360 provided protection against bafilomycin-enhanced PDT toxicity also
suggests that MCU may be responsible for mitochondrial Fe 2+ uptake. Alternatively,
interaction of MCU and Mfrn2 may be required for mitochondrial Fe 2 + transport.
This would explain why Ru360 provided such a great protection against bafilomycin-enhanced PDT toxicity (Fig. 2-6). Baughman and co-workers were not able to
show interaction between MCU and Mfrn2 in physiological conditions from their co-
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immunoprecipitation [218,219]. It may be possible that interaction of these proteins
is favored by high Fe 2+. Further studies are needed to answer these questions. Our in

vitro data show that bafilomycin greatly enhances Pc 4-PDT efficacy in Mfrn2expressing cells. The question remains whether this phenomenon also occurs in vivo.
To address this question we performed a pilot study in nude mice. Xenografts were
created with high Mfm2-expressing UMSCC22A cells and subjected to PDT (Fig. 210). Instead using bafilomycin, we employed FDA-approved chloroquine in our animal experiment. After one single PDT dose, tumors disappeared within the first 4
days post-PDT Chloroquine addition, however, significantly delayed tumor regrowth.
It would be interesting to find out the outcome if we give a second PDT dose after
tumors have begun to grow. A second treatment of chloroquine and Pc 4-PDT may
result in greater tumor regression in mice bearing high Mfm2 expressing tumors, or
may result in a higher level of tumor free mice.
In summary, the data support the conclusion that lysosomal iron release and
mitochondrial iron uptake act synergistically to induce PDT-mediated and irondependent mitochondrial dysfunction and subsequent cell killing (Fig. 3-7). Iron released from lysosomes is taken up by mitochondria through Mfm2. Downregulation
of Mfm2 prevents mitochondrial iron uptake, and delays mitochondrial depolarization and cell death. Furthermore, Mfm2 represents a possible predictive biomarker,
since HNSCC expressing more Mfm2 may benefit more from PDT.
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Figure 3-1. Differential endogenous Mfrn2 gene and protein expression in
head and neck cancer cells. Cells were cultured on 6-well plates for 24 h. (A)
total RNA was isolated, as described in Materials and Methods. Mfrn1 and Mfrn2
mRNA were quantified by real time PCR. Values are expressed as arbitrary units
(a.u.) normalized to the housekeeping rRNA 18S. Data represent the mean ± SEM
from three independent lysates. *, p < 0.01 and **, p < 0.001 compared to UMSCC22A. (B) celllysates were analyzed by Western blotting for Mfrn2, TOM20
and ~-tubulin. Blots shown are representative of 3 independent experiments. (C)
Band intensities were quantified and normalized to ~-tubulin. Values are expressed as arbitrary units (a.u.). Data represent the mean ± SEM from three independent lysates. ***,p < 0.001 compared to UMSCC1 and UMSCC22A.
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Figure 3-2. Differential mitochondria iron uptake in head and neck cancer
cells. UMSCC1 (100,000) and UMSCC22A (200,000) cells were cultured on 24well plates for 24 h. Subsequently, culture medium was changed to the lBC and
rates of the mitochondrial Fe2+ uptake were measured in digitonin-permeabilized
cells, as described in materials and methods. Values are expressed as Fe2+ uptake/min/mg protein. Data represent the mean ± SEM from three independent experiments performed in triplicate. *,p < 0.01 compared to UMSCC1.
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Figure 3-3. Mfrn2 knockdown decreases mitochondrial iron uptake. UMSCC22A cells were transfected with Mfrn2 and non-target (siControl) siRNA for
6 days, as described in Materials and Methods. (A) total mRNA was isolated and
analyzed for Mfrn2 expression by real time PCR. Mfrn2 mRNA was normalized
to internal control rRNA I8S. Values are expressed as percent of siControl values. Data represent the mean ± SEM from three independent experiments. (B)
celllysates were analyzed by Western blotting for Mfrn2 and ~-tubulin. Representative Western blot is shown. Band intensities were quantified and normalized to B-tubulin. Results are expressed as percent of siControl. (C) mitochondrial Fe2+ uptake was measured in digitonin-permeabilized cells, as described in
Materials and Methods. Values are expressed as Fe2+ uptake/min/mg protein.
Data represent the mean ± SEM from three independent experiments performed
in triplicate. *, p < 0.01 compared to siControl.

102

A

c

B

--

• siControl
o siMfrn2

100

0~

-

o'::!2.

2

cr:

2
r-

~

~

50

,..,

50

:.0

ro

>
0
0

15

Post-PDT (min)

30

OL----'--...Io...----r...-"""'------..........-

o

2

4

6

8

Time (h)

Figure 3-4. Mfrn2 knockdown confers sensitive cells resistant to PDT. (A) UMSCC22A cells were transfected with Mfrn2 and non-target siRNA for 6 days, as described in

Materials and Methods. Subsequently, cells were trypsinized and cultured (150,000/dish) on
glass-bottomed Petri dishes for 24 h. Cells were incubated with Pc 4 (0.8 pmol Pc 4/mg protein) for 18 h in complete culture medium. Cells were loaded with 250 nM TMRM and subsequently incubated with TMRM (50 nM) and bafilomycin (50 nM) for 1 h before irradiation.
Red fluorescence of TMRM was imaged with laser scanning confocal microscopy before (0
min) and every 5 min after irradiation for 30 min. Representative images from three independent experiments. Images were pseudocolored using a lookup table from 0 to 255 pixel intensities (B) average TMRM fluorescence after background subtraction under conditions described
in panel A was determined every 5 min for 30 min. Results are expressed as percent TMRM
fluorescence of 0 min. Data are means calculated from analyses of 74-80 cells per treatment
group obtained from three independent experiments (mean ± SEM). *, P < 0.05 compared to
control siRNA. (C) cells were plated on 96-well plates and treated under same conditions as in
panel A. Viability was monitored by PI fluorometry. Results are expressed as percent viability
of 0 min. Data represent three independent experiments (mean ± SEM) performed in quadruplicate. *, p < 0.05 and **, p < 0.01 compared to control siRNA.
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Figure 3-5. Localization and protein expression of the overexpressed Mfrn2-GFP
in the resistant UMSCCI cells. (A) UMSCCI cells were transiently transfected with
Mfrn2-GFP plasmid. Sub-cellular localization of the overexpressed Mfm2 protein was
observed with confocal microscopy. Red: MitoTracker Red, Yellow: co-localization
of MitoTracker Red and GFP. Mfrn2-GFP protein is imported to mitochondria. (B)
Mfrn2-GFP plasmid was transfected into the resistant UMSCCI cells. After transfection (72 h), celllysates were probed for GFP, Mfrn2 and ~-tubulin, respectively as indicated.
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prior to light exposure. Viability was monitored by PI fluorometry. Results are expressed as percent viability of 0 min. Data represent three independent experiments
(mean ± SEM) performed in quadruplicate. *, p < 0.05 compared to control GFP
plasmid transfected UMSCC1 under baf+Pc 4-PDT treatment.
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Figure 3-7. P~oposed mechanism of interplay between lysosome and mitochondria and role of iron and Mfrn2 contribute to PDT -induced cell death. Pc 4PDT induces mitochondrial ROS production resulting in apoptotic cell death.
Bafilomycin (Bat) enhances Pc 4-PDT-mediated cell killing by releasing iron from
lysosomes. Cytotoxicity is decreased by iron chelators DFO and sDFO, and Ru360
that prevent mitochondrial iron accumulation. Knock-down of Mfrn2 delays mitochondrial depolarization and cell death induced by bafilomycin during PDT.
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Role of DMTI in lysosomal iron release after bafilomycin
Although bafilomycin and chloroquine have been shown to release iron from
lysosomes into cytosol, the detailed mechanism by which bafilomycin releases iron
from lysosomes remains unclear. The fact that ferristatin, an inhibitor of the DMT1,
completely reversed bafilomycin-enhanced Pc 4-PDT cytotoxicity suggests DMTI
as a likely mechanism of lysosomal iron release with bafilomycin. Since ferristatin
may have off-target effects, knockdown DMTI using siRNA method could be further used to confirm results with ferristatin. DMTI knockdown should protect
against PDT toxicities (ROS formation, mitochondrial depolarization, cell death,
etc.). Similar results are expected with knockdown of Mfm2. However, since Mfm2
knockdown did not produce 100% inhibition of Mfrn2 expression (Fig. 3-3B), some
iron is still being taken up by mitochondria. Therefore, ferristatinJDMTl knockdown
,.,

in combination with Mfrn2 knockdown may be even more efficient in decreasing
PDT toxicities than either treatment alone.

Mitochondrial iron regulation
Mechanisms underlying mitochondrial iron uptake are not completely known.
Our results show that Mfm2 regulates mitochondrial iron uptake in pathological situations such as PDT. MeU also transports iron into mitochondria when cytosolic iron
concentration is increased [205, 222]. Ru360 is a highly specific inhibitor of the

Mev.

Ru360 and knockdown of Mfm2 both prevented mitochondrial iron uptake
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and protected cells from bafilomycin-enhanced PDT.

It remains unclear whether

Ru360 also blocks mitochondrial iron uptake through Mfrn2. Also, the question remains whether interaction of Mfm2 and MCV is required for mitochondrial uptake.
A recent study showed that Mfm2 and MCV are two distinct proteins and do not interact with each other [218, 219]. However, this experiment was performed in physiological conditions.

It remains unclear whether increased cytosolic iron during

pathological conditions induces interaction of these proteins.
Mfm2 has six transmembrane helices and MCV has two transmembrane domains with a short amino acid link termed DIME motif between these two transmembrane helices [200, 218, 219] . Recent reports from two different groups concurrently demonstrated that MCV and Mfm2 are two distinct proteins and do not interact between with each other, as assessed by immunoprecipitation [218, 219]. Ru360

..,

is a specific inhibitor of MCV [205], and. our results showed that Ru360 markedly
protect against bafilomycin-enhanced mitochondrial depolarization and Pc 4-PDT
killing (Fig. 3-6) [92].
MCVIMfrn2.

This implies some interaction between Ru360 and

Overexpression of MCV confers cells slightly resistant to Ru360

whereas mutation on the DIME linker motif confers cells remarkably resistant to
Ru360 [219]. These findings suggest that the linker region between the two transmembrane helices of MCV is important for Ru360 sensitivity. Mfm2 may share
Ru360 sensitivity with MCV though the DIME motif. Further studies are needed to
address this issue.
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Signaling pathways induced by bafilomycin-enhanced Pc 4-PDT
MAPK kinase pathways are frequently induced during mitochondrial stress
[231, 232]. Iron released from lysosomes with bafilomycin and taken up by mitochondria via Mfrn2 depolarizes mitochondria and causes onset of apoptotic cell
death during PDT.

We have performed preliminary experiments to determine

whether JNK pathway is involved in PDT. Our preliminary results from Western
blotting showed PDT plus bafilomycin-induced increase of phospho-JNKl/2 protein
expression (data not shown). These findings suggest JNK to be a possible killing
pathway induced during bafilomycin-enhanced Pc 4-PDT killing. Future experiments
should be performed to confirm the role of JNK pathway in bafilomycin-enhanced
Pc 4-PDT killing. The interesting question would be inside the cells whether JNK is
activated in cytosol or mitochondria.

.,
In vivo studies
Pc 4 is a potent photosensitizer and has shown promising efficacy without any
safety issues in phase I clinical trial [98]. However, single drugs are unable to cure
most cancers. The same limitation applies to PDT as a sole modality. Thus, combining PDT with other modalities to improve the therapeutic index has received much
interest [201, 233, 234]. Furthermore, using PDT in solid tumors is challenging.
Higher photosensitizer dosages may be required to achieve sufficient concentration
deep in tumors. However, high dose photosensitizer may increase accumulation in
normal tissues that might also be exposed to light ( skin, eyes). Insufficient light pen-
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etration, whether from surface-illumination or from implanted fibers, and decreased
oxygen tension deep in poorly vascularized tumors can result in decreased formation
of 102 and other ROS, thereby diminishing the therapeutic effect of PDT. A primary
determinant of PDT efficacy is the extent of ROS (including 102) production. Thus,
manipulations that increase intracellular ROS production within tumors during PDT
should increase treatment efficacy.
Our pilot experiments show that adjuvant treatment with chloroquine enhanced
tumor response to Pc 4-PDT especially in high Mfm2 expressing tumors. These results suggest that Mfm2 expression levels in tumors could be utilized as a biomarker
predicting response to PDT.

It would be interesting to measure Mfrn2

mRNAIprotein levels in tumor samples from head and neck cancer patients and see
how much variation is in Mfrn2 expression levels among patients. If there is a varia,

tion between samples, then patients with high Mfrn2 expressing tumors would benefit from adjuvant treatment of chloroquine during PDT.

Nanoparticies
Although PDT is an effective treatment it may have some off target effects,
since systemic delivery of the photo sensitizers distribute them throughout the body.
An ideal situation would be to deliver the photosensitizer exclusively into tumors.
Recent studies have focused on applying nanoparticles conjugated to Pc 4 to increase
its cellular overall uptake and delivery [112]. Nanoparticles have also been decorated
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with a small peptide of epidermal growth factor (EGF) that directs them to cancer
cells overexpressing receptors for EGF [235, 236]. Since many tumors overexpress
EGF receptors, this is an efficient way to deliver Pc 4 specifically into tumors.
Therefore, future studies can be focused on Pc 4-conjugated nanoparticles that can be
decorated with various cancer-specific molecules to enhance specificity of PDT in
vivo studies.

,

...
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Significance and Conclusion
To our knowledge, we are the first group to demonstrate that iron released
from the lysosome and taken up into the mitochondria enhances mitochondrial Pc 4PDT cytotoxicity [92]. In addition, our study here demonstrates that Mfm2 plays the
essential role for PDT response in cancer cells. In conclusion, our results demonstrate that both the lysosomal event of iron release by bafilomycin and the mitochondrial event of iron uptake by Mfm2 are required as two hits to enhance Pc 4-PDT
efficacy in vitro. Furthermore, our preliminary in vivo results also extend and confirm our in vitro finding of lysosomal alkalinization reagents enhancing the PDT killing and impeding tumor regrowth. Taken together, we demonstrated that iron is an
essential factor for mitochondrial PDT efficacy, and Mfm2 represents a possible biomarker for cancer response to Pc 4-PDT as well as a means to guide therapy choice

.

,..

during PDT treatment.
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